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ABSTRACT 
Interdisciplinary multimodal pain rehabilitation (IMPR) is currently considered best practice 
for combatting chronic pain. However, it is believed that health-related outcomes could be 
improved with more adequately tailored treatment programs, but consensus of what grounds 
these adaptations should be based on is yet to be reached. Well-powered evaluations of 
naturalistic, real-world practices provide an evidence base for the evaluation of important 
characteristics that may facilitate the informed development of IMPR. The aim of the present 
work was to meta-synthesize existing evidence and add new data to the body of published 
evidence on prognostic factors for a positive outcome in patients receiving rehabilitation for 
chronic pain. An additional aim was to evaluate the effectiveness of different IMPR program 
durations on health-related quality of life in this major patient group. 
Methods: Published international evidence of prognostic factors for physical functioning 
after IMPR was evaluated through a systematic review and meta-analyses (Study I), followed 
by the investigation of the inter-rater reliability of the Quality in Prognostic Studies tool 
(QUIPS), used in the Risk of Bias assessment (Study II). Prognostic factors (Study III) and 
effectiveness (Study IV) of Swedish pain specialist IMPR on physical and mental functioning 
and related measures of disease impact were investigated using large-scale nationwide data 
obtained from the Swedish Quality Registry for Pain Rehabilitation.  
Results: Meta analyses showed, with moderate to low levels of evidence, that better physical 
functioning at follow-up was predicted by high levels of self-reported functioning, low levels 
of emotional distress and cognitive-behavioral risk factors, and high levels of cognitive-
behavioral protective factors. Pain-related factors (intensity and chronicity) were not 
associated. Weak to moderate inter-rater agreement emerged for QUIPS, and suggestions for 
improving the inter-rater agreement and functionality were presented. Swedish registry data 
showed the most important prognostic factors were retaining a connection with work, having 
high optimistic treatment expectations, sense of control, and less interference from pain. Pain 
itself was of secondary significance. Also for improvement of physical functioning, better 
initial mental wellbeing was of importance, while for mental functioning the opposite emerged. 
Results on within-group effectiveness showed improvements on all outcomes, while no 
between-group comparison emerged on short (4-9 wks) vs. moderate (10 wks) vs. long (11-18 
wks) IMPR program duration. 
In summary, evidence for prognostic factors was identified, providing suggestions for the 
targeting of modifiable factors in clinics and in future clinical trials. Clearly, the quality 
assessment of published results needs systematic consensus work between assessors. Work 
connection, treatment expectations, levels of physical and emotional health, and coping 
strategies played an important prognostic role but were not consistent for physical and 
emotional functioning, suggesting a complex prognostic picture for the overall understanding 
of improvement. Finally, IMPR is effective across a biopsychosocial specter, but treatment 
duration seems not to play an important role.  
 SVENSK SAMMANFATTNING 
Multimodal smärtrehabilitering (MMR) anses vara bästa praxis för behandling av kronisk 
smärta. De påvisade effekterna på olika (biopsykosociala) hälsorelaterade resultat är dock 
suboptimala. Det antas att rehabiliteringsresultat kan förbättras med mer adekvat anpassade 
behandlingsprogram, men fortfarande saknas konsensus om vilka faktorer dessa anpassningar 
bör grundas på. Effektiva utvärderingar av reell klinisk verksamhet kan ge en grund för 
utvärdering av viktiga egenskaper som kan bidra till utveckling av MMR. Syftet med detta 
avhandlingsarbete var därför att meta-syntetisera befintlig evidens, och att komplettera med 
nya primärdata till kunskapsunderlaget om prognostiska faktorer för ett positivt 
behandlingsutfall hos patienter med kronisk smärta som genomgått rehabilitering. Syftet var 
vidare att utvärdera effektiviteten av MMR som genomförs med olika behandlingslängd, med 
avseende på hälsorelaterad livskvalitet i denna omfattande patientgrupp med kronisk smärta. 
Publicerade internationella resultat vad gäller prognostiska faktorer för fysisk funktion efter 
MMR utvärderades genom en systematisk litteraturgranskning och meta-analyser (Studie I). 
Denna studie följdes av en undersökning av inter-bedömarreliabilitet (tillförlitlighet) för ett nytt 
kvalitetsbedömnings-instrument avsett för prognostiska studier- ”QUIPS”, ett instrument som 
används vid bedömning av Risk för Bias (Studie II). Prognostiska faktorer (Studie III) och 
effektivitet (Studie IV) vid svensk MMR (specialistnivå) med avseende på fysisk och psykisk 
funktion, samt konsekvenser av smärta, utvärderades med hjälp av omfattande registerdata från 
Nationella Registret över Smärtrehabilitering, NRS. 
Metaanalyser visade, med måttlig till låg evidens, att bättre fysisk funktion vid uppföljning 
förutspåddes av högre nivåer av självrapporterad funktion, låga nivåer av mental ohälsa, och 
kognitiva beteende-riskfaktorer samt höga nivåer av skyddande kognitiva beteende-faktorer. 
Smärtrelaterade faktorer (intensitet och duration) var inte associerade. Överenstämmelse vid 
Risk för Bias-bedömningar med QUIPS var svag till måttlig, och förslag till att förbättra 
överrensstämmelse och funktionaliteten presenterades. Svenska registerdata visade att de 
viktigaste prognostiska faktorerna generellt var att vara i arbete, ha optimistiska 
behandlingsförväntningar, känsla av kontroll och mindre funktionsstörningar från smärta. 
Smärta i sig var av sekundär betydelse. För fysisk funktion specifikt var ett gott mentalt 
välbefinnande av betydelse medan för mental funktion var ett lägre (dåligt) utgångsvärde av 
betydelse. MMR som helhet var effektiv vid behandlingsuppföljning för alla utfallsvariabler. 
Ingen skillnad framkom dock vid jämförelse mellan grupper med olika behandlingstid. 
Sammanfattningsvis identifierades evidens för att det finns viktiga prognostiska markörer, 
vilket pekar på modifierbara faktorer användbara i såväl klinisk verksamhet som för framtida 
randomiserade kliniska studier. Det är tydligt att kvalitetsbedömning av publicerade resultat 
kräver systematiskt konsensusarbete mellan bedömare. Att vara i arbete, ha positiva 
behandlingsförväntningar, samt lägre ingångsvärden på de respektive utfallen, fysisk och 
emotionell hälsa, samt copingstrategier, spelade en viktig roll för det framtida 
  
behandlingsresultatet. Resultaten var dock inte konsekventa för fysisk och emotionell funktion, 
vilket antyder en komplex prognostisk bild för förståelsen av klinisk förbättring som helhet. 
MMR är en effektiv behandlingsmetod från ett biopsykosocialt perspektiv, men dess 
behandlingslängd verkar inte ha någon betydande roll för det framtida behandlingsresultatet. 
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1 INTRODUCTION 
 
“My pain never takes time off, it has a will of its own”    
 “My pain and I now live together. Not always in harmony.”  
 
Chronic pain conditions result in wide-ranging negative effects on a person’s life and are 
associated with a great amount of suffering. Health-related quality of life in patients with 
chronic pain has actually been reported to be among the lowest of any medical condition. In 
addition to discomfort and distress for the affected individuals, chronic pain imposes a 
considerable economic burden on the health care system and society as a whole and, despite 
all efforts, it is increasing – chronic pain is now regarded as an epidemic condition. 
Interdisciplinary multimodal pain rehabilitation (IMPR) is currently the preferred treatment for 
chronic pain. It was first described in the 1970s, has been continuously developed since then, 
and has now solidified its position within the health care systems of the Western world. In 
Sweden, approximately 40 clinics specializing in the treatment of chronic pain offer IMPR (in 
Sweden commonly referred to as Multimodal Rehabilitation, MMR) to patients with significant 
levels of persistent pain. Current research reports the effectiveness of IMPR to be only 
moderate, but despite this it is considered to be the best practice available today. There is, 
however, a great need to further increase knowledge regarding the selection and adaptation of 
treatment so it better matches patients’ needs, especially since IMPR is costly and patients are 
selected for different treatment approaches based on limited evidence and local clinical 
preferences. There is a need for evidence built on larger sample populations and a higher 
number of clinics in order for a representative evaluation of pragmatic practice to be possible. 
This, in turn, could further indicate areas for future detailing with experimental designs. 
This thesis was designed with the long-term general goal of helping improve health care in 
general and specific goal of helping individuals with chronic pain in the health care system. 
The project adopts a longitudinal design where IMPR is prospectively evaluated with respect 
to pain, functioning, and health-related quality of life. It addresses the challenge of combating 
chronic pain and constitutes a key passage to a translational process, and is designed to evolve 
current knowledge through realistic results derived from practice-based evidence. It includes 
four studies; the first is based on data from published original studies included in a systematic 
review and meta-analysis, the second is based on data from method evaluation as part of the 
system review, and the remaining two are founded on nationwide data from the Swedish 
Quality Registry for Pain Rehabilitation (SQRP). By using a large sample approach founded 
on both national and international multicentre data, it is hoped that this study will contribute to 
existing evidence on prognostic factors and the effectiveness of IMPR – currently the best 
available, yet still suboptimal, treatment for chronic pain.  
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1.1 PERSPECTIVE AND THEORETICAL FRAMEWORK 
This thesis is based on a positivistic perspective, with a deductive approach applied to the 
research questions, as often seen in quantitative research. The project investigates an 
interdisciplinary research field, and as such expands to broadly encompass rehabilitation 
medicine and public health. Figure 1 gives an overview of the thesis topic, research questions, 
and used data sources.  
 
Figure 1. Overview of topic, research questions and data sources of the thesis. 
 
The present thesis addresses interdisciplinary rehabilitation as a way to improve health in 
people with chronic pain, making the concept of health central. A commonly used definition 
of health, endorsed here, is from the World Health Organization (WHO) in 1948: “Health is a 
state of complete physical, mental and social wellbeing and not merely an absence of disease 
or infirmity”, later complemented with “the ability to lead a socially and economically 
productive life” (1, 2). Health here is, therefore, described as a bio-psychosocial concept, which 
also involves contextual factors. The health model of the International Classification of 
Functioning, Disability, and Health (ICF) can be used as a reference for the description of a 
person’s health condition and provides a language to depict consequences of this health 
condition. The overall term in the framework is Functioning, which covers all body functions, 
activities, and participation, while Disability, on the other hand, is an overall term for 
impairments, activity limitations, and participation restrictions. The model also addresses 
interacting contextual factors that are both personal and environmental (3). The ICF model thus 
reflects the multidimensionality of the health concept, however, it does not depict the equally 
central concept of health-related quality of life (HRQoL), which is addressed in this thesis. It 
has been suggested that the dimension quality of life as concept can be imagined as the ‘circle 
around the ICF-model’(4). In HRQoL, perceived physical and mental health are believed to 
constitute core dimensions (5), and therefore in this thesis, the term is used as an umbrella term 
for our main outcomes.  
  3 
2 BACKGROUND 
 
2.1 PAIN - DEFINITIONS AND TERMINOLOGY  
2.1.1 Pain 
The International Association of the Study of Pain (IASP) endorses the definition of pain as 
“an unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (6). This definition emphasizes that pain refers 
to an experience and is, therefore, always subjective. It is “unquestionably a sensation in a part 
or parts of the body, but it is also always unpleasant and therefore also an emotional experience” 
(7). As such, the experience of pain is inherently multidimensional by nature. Still, a criticism 
to the above definition is that other major dimensions of the pain experience are excluded, 
which are equally important from a clinical perspective. Probably there is no perfect definition 
for the abstract and subjective phenomenon of pain, but the following suggested additional 
dimensions are of great relevance, in particular where chronic pain is concerned: “Pain is a 
distressing experience associated with actual or potential tissue damage with sensory, 
emotional, cognitive, and social components.”(8).  
 
2.1.2 Chronic pain  
Several starting points for the classification of pain exist, e.g. temporal, etiological, or 
mechanism-based. When pain persists and exceeds, a pre-defined temporal cut-off is 
commonly used and pain lasting for a period of ≥3 months, or beyond the point of normal tissue 
healing, is referred to as persistent or chronic pain (6). However, classifying chronic pain by 
duration solely has some shortcomings from a clinical perspective. Moreover, the vocabulary 
used for common chronic pain conditions is not very consistent; sometimes it is based on the 
anatomical location of pain (for instance chronic low back pain, neck pain, or widespread pain), 
or on the pain mechanisms involved (nociceptive, inflammatory, neuropathic, and recently 
nociplastic pain) (9). More focus on identifying the underlying pain mechanisms is believed to 
be very important for the pain management selection process (10). 
It has long been argued that although etiology, localization, and diagnoses might differ, chronic 
pain itself could be considered “a disease in its own right” (11). Hence, in view of the 11th 
revision of the International Classification of Diseases (ICD) (12, 13), the application for a 
separate diagnostic code for chronic pain in the updated classification system is intended to 
better reflect the actual epidemiology of chronic pain conditions, which will in turn better 
facilitate their clinical management. 
Chronic primary pain is defined as pain in one or more anatomical regions that (1) persists or 
recurs for longer than 3 months, (2) is associated with significant emotional distress (e.g. 
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anxiety, anger, frustration, or depressed mood) and/or significant functional disability 
(interference to activities of daily life and participation in social roles), and (3) the symptoms 
are not better accounted for by another diagnosis. 
 Chronic musculoskeletal pain 
Chronic musculoskeletal pain represents the most prevalent set of chronic pain conditions and 
includes the vast majority of chronic pain conditions that are the focus of this thesis. In 
accordance with the new ICD-11 definition of chronic pain, the majority of these non-
malignant and non-systemic disease pain conditions would be classified as chronic primary 
pain (12) or chronic musculoskeletal pain (primary, secondary, or nonspecific) (14). In this 
thesis, the term “chronic musculoskeletal pain” will be referred to as synonymous with the term 
“chronic pain”.  
 
2.2 CHRONIC PAIN 
2.2.1 Epidemiology 
The World Health Organization (WHO) recognizes chronic pain as the leading global public 
health problem with 27% of the adult population living with chronic pain of significant 
intensity (15). Of all the chronic pain conditions, musculoskeletal diseases are predominant, 
prevalent in nearly one third of the population (16). This type of chronic pain is the most 
common cause of long-term disability in middle-aged people (17). Years lived with disability 
(YLDs) is a measure of non-fatal health outcomes, and pain conditions have been found to 
cause 21% of all YLDs globally. In a Lancet study published in 2017 (18), low back pain 
emerged as the leading single cause for YLDs followed by major depression disorders, anemia, 
and neck pain. These leading causes were significant when scaled to Europe and Sweden as 
well. The problem also seems to be increasing in both Sweden and worldwide. Chronic pain is 
also reportedly associated with an increased risk of mortality, even when controlled for socio-
demographic factors (19, 20). Taken together, chronic pain presents a major public health 
problem with major health cost implications for society (15). 
 
2.2.2 The societal burden of chronic pain 
Chronic pain causes a considerable economic burden on society that significantly affects every 
country’s GDP. Chronic pain is also associated with a high degree of health care consumption 
(15) and frequently results in long-term absences from the workplace (>180 days). This 
constitutes major socioeconomic problems not only for individuals but also for health care 
systems and societies as a whole. In Sweden, the costs for chronic pain in the form of social 
insurance costs for sick leave and loss of production have been estimated by the Swedish 
Agency for Health Technology Assessment (SBU) to be 90 billion Swedish kronor 
(90,000,000,000 SEK) annually (21). And the cost of musculoskeletal disorders represented 
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31% of total health costs in Sweden, the second largest expenditure on healthcare in Sweden, 
exceeded only by costs associated with all mental illnesses together (22). 
 
2.2.3 Etiology 
The mechanisms that underlie a transition of acute musculoskeletal pain into chronic pain are 
only partially uncovered, and although huge advances in the field have been made in recent 
years, the etiology behind why some people develop chronic pain and others do not still remains 
unclear (23, 24). Acute musculoskeletal pain is often triggered by injury or the overload of 
musculoskeletal structures (muscles, tendons, ligaments, joints, and skeletal structures) causing 
inflammatory, ischemic, or degenerative processes (25) that result in nociceptive pain (25). 
Low back pain, neck pain, and myalgia, for instance, are common benign musculoskeletal 
disorders that often occur and, most commonly, the initial acute pain associated with them will 
decline in due time as healing occurs (23).  
Taken together, advances in the field of neurobiology have led to a wider understanding of 
chronic pain, but the exact underlying pathophysiology is still undetermined. In the past 50 
years, knowledge of mechanisms in pain transfer and modulation has increased rapidly. 
Milestones such as the Gate Control Theory in 1965 (26), the Neuromatrix Theory of Pain in 
1999 (27), and more recent advances in pain physiology and imaging techniques, have all 
provided evidence of complex mechanisms acting within the nervous system; how alterations 
occur that may contribute to the experience of pain by activating pain memories in the absence 
of peripheral input, or by exaggerating noxious or non-noxious inputs. This explains how 
neurobiological changes can occur even in the absence of injury or inflammation, which can 
partly explain the mechanisms of persistent pain. Central sensitization is considered to play an 
important role in chronic pain conditions and refers to neural alterations that may perpetuate 
and heighten the pain signal. Some of the pain facilitating mechanisms are a) increased 
reactivity (sensitization) in the peripheral and central nervous system, e.g. wind up, b) increased 
sensitivity to pain, e.g. hyperalgesia and allodynia, and c) decreased (dysfunctional) 
endogenous pain inhibition (28, 29). A complex functional network, the Neuromatrix, and its 
related modulations by somatosensory, endocrine, immunological, and autonomous systems, 
is activated in pain, and emotional and cognitive processes influence both inhibitory and 
facilitatory processes (30). 
 
  Risk factors for developing chronic pain 
The complex and multifactorial nature of pain challenges knowledge of set risk factors for pain 
persistence and development of chronic pain conditions. High initial pain intensity that 
markedly affects everyday life and long pain duration are suggested risk factors. Several other 
factors of importance have come forth as well, displaying a biopsychosocial panorama; 
personal characteristics e.g. advanced age, female sex, non-native ethnicity, comorbidity and 
 6 
self-reported low health, psychological factors such as high psychological loading, inadequate 
coping strategies and avoidance behavior, socio-demographic and work related factors 
including high physical demands and a negative psychosocial environment, and long periods 
of sick leave (28, 31-34). Hence, a wide range of possible risk factors has been proposed and 
amongst these, psychosocial factors are believed to play a greater role along with increasing 
chronicity. Efforts to identify these early, for instance through specific questionnaires, seem 
important for efforts made to avoid transitioning from an acute to a chronic problem (35). 
Several biological, psychological, and socio-demographic components may have an impact on 
this process, which necessitates the biopsychosocial approach for this multifactorial 
phenomenon (34).  
 
2.2.4  A biopsychosocial understanding of a complex condition 
Chronic pain is a complex condition, differing from acute pain in more ways than simply 
duration. A multifaceted and dynamic interaction between physiological, psychological, and 
social factors are involved in numerous processes that perpetuate, and even strengthen, one 
another resulting in complex conditions with chronic pain and disability (30). To understand 
and treat chronic pain, a biopsychosocial approach is regarded as fundamental, and this should 
be reflected in all meetings with the patient throughout treatment – from the first encounter, to 
the assessment, planning and implementation of intervention as well as in evaluating treatment 
effects (30). The biopsychosocial model, initially proposed by GL Engel in 1977 (36) was 
introduced to expand the traditional biomedical perspective which was too narrow to hold the 
complexity of the condition and hence hindered an optimal treatment approach (30). The model 
has been increasingly influential in the field of pain, especially as a model to understand chronic 
pain. 
Pain, its interference in most daily activities and decreased functioning are common 
consequences of chronic pain resulting in physical deconditioning over time (37). When pain 
lasts for a longer period of time, emotional and behavioral components have more opportunity 
to interact with the social environment. Pain generates frustration and fear, affecting both the 
person afflicted and his/her environment. This psychological distress may result in anxiety and 
depression disorders and, in addition to the emotional agony, it is not uncommon for sufferers 
to experience additional stress, such as financial stress from reduced work ability, marital and 
family dysfunction, substance abuse and dependence, and a general decline in social and 
recreational functioning (38). Chronic pain results in social and psychological consequences 
and affects work, leisure, future perspectives, and self-image. Pain, in addition to its 
consequences, may lead to inhibited participation in society. Marginalization from work, 
alienation within families and relationships, and otherwise restricted engagements in active 
everyday life are frequent. Still, the impact and extent of the consequences vary, some may 
have more limited negative consequences while others experience severe pain and 
overwhelming distress (39, 40). 
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Sufferers of chronic pain score one of the lowest HRQoL scores, equal to that of patients with 
advanced cancer in palliative care (41). The psychosocial aspects of pain were the predominant 
reason for this rather than the pain intensity itself. The overall picture of consequences of 
chronic pain hence extends over all dimensions of an individuals’ functioning, activity, and 
participation as depicted in the ICF health model, and are influenced by personal as well as 
environmental factors (42). Hence, any efforts to treat such a complex condition must naturally 
encompass these dimensions in therapy in order to be successful, and therefore complex 
interventions have gained acknowledgement in the field of pain rehabilitation. 
 
2.3 INTERDISCIPLINARY MULTIMODAL PAIN REHABILITATION 
Rehabilitation medicine forms the extension of curative medicine and specializes in treating 
complex medical conditions accompanied by longstanding disability. Three rehabilitation 
procedures have been described for chronic pain, depending on the amount of measures 
applied; 1) Unimodal rehabilitation, where one single modality is applied, e.g. physiotherapy 
and the intervention is performed by healthcare workers from one profession, although it may 
include different approaches (43). 2) Intermediate rehabilitation, where more measures are 
applied by healthcare workers from different professions who may convene in teams but 
provide their treatment independently, and 3) Interdisciplinary multimodal pain rehabilitation 
(IMPR), which is the most complex intervention involving a set team of several healthcare 
workers representing a number of professions, and with the patient being an active member of 
the team (28, 44). 
 
2.3.1 Definition of Interdisciplinary multimodal pain rehabilitation 
There is a vast use of different terminology used in both literature and clinical practice for these 
complex treatment approaches, which is why the IASP recently proposed using unified 
terminology, with the term interdisciplinary treatment to be used for: “Multimodal treatment 
provided by a multidisciplinary team collaborating in assessment and treatment using a shared 
biopsychosocial model and goals.” A similar expression, which also is being increasingly used, 
is Interdisciplinary Multimodal Pain Therapy (IMPT) (45). In Sweden, IMPR is often referred 
to as multimodal rehabilitation (MMR) or multidisciplinary rehabilitation (MDR). The term 
IMPR will be used in this thesis and is synonymous with these Swedish terms.   
 
2.3.2 Therapeutic targets, composition, and administration of IMPR 
IMPR is directed towards all the diverse components of the pain experience as well as their 
consequences. It targets functioning and the psychosocial dimensions of chronic pain, and, by 
extension, health-related quality of life. Central features are based on behavioral medicine and 
theories on learning, using a cognitive behavioral therapy approach to address patient 
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cognitions, emotions, and behaviors with the aim to improve functioning and coping ability. 
Its approach considers each patient’s needs from a bio-psycho-social perspective, including 
work or employment status. IMPR generally includes patient education and supervised 
physical activity/exercise therapy as one of the core treatment options along with psychological 
measures, occupational therapy sessions, ergonomics, and pharmaceutical treatments if needed 
(46, 47). IMPR is administered by specialized interdisciplinary teams, usually consisting of 
physicians, psychologists, physiotherapists, occupational therapists, social workers, and other 
healthcare professionals (21). 
A rehabilitation plan is formed in collaboration with the patient. Most interventions are group-
based but each patient has an individual plan, schedule, and individual contacts according to 
his/her own goal setting (28, 48). IMPR-measures are expected to act both on their own (21, 
47) and in conjunction with each other, equivalent to what has been defined as a complex 
intervention by Medical Research Council guidance (49). The sum of these parts is supposedly 
greater than if they were provided unimodally.  
IMPR dosage is an equally complex matter to delineate. Evidence is still unclear on whether 
more or less optimal administrations of IMPR exist with regard to time aspects, such as how 
long a treatment program should be in order to be effective and if intensity should be viewed 
in this context. Comparisons of the composition, intensity, and duration of IMPR programs 
remain inconclusive (50). Principles of behavior change imply that behavioral changes require 
time to learn and practice and therefore interventions should provide sufficient time to adopt 
these skills into daily life (51, 52). Healthcare professionals’ experience also add to that 
treatment length is of importance for learning and implementation to take place (53). However, 
until now, there has been no available empirical evidence of the duration of treatment programs 
having an influence on the success of the intervention (47, 50). 
 
 IMPR in Sweden 
IMPR is currently offered by approximately 40 specialist clinics throughout Sweden. Patients 
of working age with benign chronic pain from the musculoskeletal system who experience 
complex adverse effects from this in their lives can be referred to participating clinics for 
investigation and/or interdisciplinary rehabilitation. The referrals to participating clinics come 
primarily from primary care and private general practitioners, but also from other clinics and 
hospitals.  
Patients are initially assessed by a multidisciplinary team through interviews and examinations, 
and patients with potential “red flags”, such as history of trauma, unexplained weight loss or a 
cancer history, are excluded before a rehabilitation plan is formed. With a focus on increasing 
accessibility and effectiveness, two levels of IMPR treatment plans have been set; MMR 1 for 
less complex pain conditions, mainly provided in primary care, and MMR2 for extensive and 
more complex pain conditions, primarily provided by specialist clinics. All of Sweden’s 
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specialist clinics are linked to a quality registry, the Swedish Quality Registry for Pain 
Rehabilitation (SQRP) for the purpose of treatment evaluation and development.  
 
2.3.3 Outcomes in rehabilitation of chronic pain 
Pain, physical functioning, and emotional functioning are core outcome domains suggested by 
the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) 
group (54), along with participant satisfaction with treatment and symptoms or adverse events. 
The importance of evaluating multiple outcome domains was confirmed consistently across 
pain conditions in a large survey of people with chronic pain (55), and it has therefore been 
suggested that it is included in the study of the efficacy/effectiveness of chronic pain treatments. 
A variety of appropriate measures for these patient-reported outcome measures exist, 
commonly referred to as PROMs (Patient-Reported Outcome Measures) and PREMs (Patient-
Reported Experience Measures). They adhere to the multidimensionality and subjective 
reporting of the experience of pain, as emphasized by the IASP definition of pain. The majority 
of targeted outcomes are thus assessed by PROMs, both regarding pain, and physical and 
emotional functioning. Physical functioning is an important outcome domain, as patients 
experience major restrictions due to functional problems which extend across all domains of 
the ICF model. Physical functioning is also a broad construct, and can be measured in several 
ways; performance based or through self-reporting, but predominantly in the field of IMPR it 
is measured though PROMs. There is an abundancy of measures, some measure pain-related 
physical functioning specifically, while others measure general physical functioning. When 
evaluating treatment benefits related to physical functioning and functioning in general, one 
can assess either proximal aspects of functioning, closely related to the core signs and 
symptoms of the disease, or more distal and general disease impact concepts such as general 
physical, psychological, and social functioning and, by association, general life concepts such 
as health-related quality of life (56).  
 
2.3.4 Prognosis in IMPR 
Prognosis refers to a likely future outcome; in this context it refers to the likely health outcomes 
of people who participate in IMPR. Prognostic factor research aims to identify factors 
associated with better or worse outcomes, in order to inform therapeutic decisions and help 
identify interventional targets that may help modify the likely course of the condition (57). 
Knowledge of factors of importance for the prognosis of treatment outcome is vital but greatly 
limited, and in the field of IMPR the body of evidence is still insufficient to provide any 
guidance. It is currently unclear which factors, patient related and/or treatment related, are 
essential for treatment success, and which indicate a risk for a poor prognosis (21). Previous 
reviews investigating prognoses for a range of core outcomes on diverse chronic pain, 
fibromyalgia (58), or chronic low-back pain populations (59, 60) have identified some patient 
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characteristics (i.e. prognostic factors) including patients’ initial levels of depression, initial 
pain intensity, and work-related functioning and active coping skills. 
The prevailing evidence, however, is mainly based on narrative syntheses, as the included 
studies were considered too heterogeneous for data to be pooled for a meta-analysis. The 
authors of systematic reviews on IMPR outcome predictors generally conclude that studies are 
of low quality, often using a simple exploratory design, making the identification of a 
universally valid set of predictors impossible. In general, combinations of predictors seem more 
important than single predictors, in accordance with chronic pain being a complex 
multifactorial problem. The SBU and national networks acknowledge the importance of 
acquiring a better evidence base for prognosis, in order to gain guidance on selecting and 
customizing the best possible invention for each individual case.  
 
2.3.5 Effectiveness in IMPR 
IMPR for chronic pain has been evaluated and, as indicated, is generally considered more 
effective than unimodal or less complex interventions (21, 47, 48, 61-63). Conducting high-
quality research into IMPR has been recognized as a major challenge due to the complexity of 
the conditions and diverse nature of the IMPR programs, with respect to content and intensity 
(or dosage as defined herein). To date, there is little scientific literature on how IMPR 
interventions should be designed to optimize results (45). It is still unknown which treatment 
components are really important, and whether all components benefit patients alike (47). This 
lack of evidence has delayed the improvement of existing IMPR programs. IMPR is expensive 
and time-consuming, and clinical departments actively select which patients are offered this 
intervention. 
In addition to patient-related factors, other factors such as the specific orientation of the IMPR 
program and its dose may relate to the treatment itself and have interactions with different 
patient characteristics. Due to the limited number of studies investigating such variations, the 
effects of these still remain unclear, delaying evidence on whether some treatment modalities 
work better in some types of patients. 
In an attempt to evaluate the effects of different IMPR intensities, which is one ingredient of 
dosage, Haldorsen et al. (64) found that patients with a good prognosis appeared to benefit from 
any intensity whereas patients with a poor prognosis benefitted only from extensive IMPR. 
However, their data suffered from selection bias as only 33% of those invited agreed to 
participate, and participants were recruited from only one outpatient clinic.  
In addition to uncertainties regarding IMPR intensity, there is also a lack of knowledge 
regarding the optimal duration of IMPR programs, which range from four to 18 weeks in 
Sweden. Duration, which is another ingredient of dosage, seems to be often based on local 
tradition and medical staff preferences. IMPR duration is certainly complex and cannot be 
directly transferred from pharmacotherapeutic principles, but the topic has been extensively 
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discussed in pain rehabilitation networks and patient associations and has been acknowledged 
in the latest SBU report (21). The importance of program duration can be stressed since 
treatment strategies involving behavioral changes including adherence to physical exercise 
elements of a program take time in chronic pain conditions (52, 65). Preliminary data from a 
report on a limited sample indicate that a 12-week IMPR program is superior to a comparatively 
shorter IMPR program where health-related quality of life is concerned. However, further data 
from multiple centers is required, and the focus of future evaluations should also include cost-
effectiveness, which has been requested for a long time (15). 
In summary, there is an urgent need, called for by the healthcare community (4, 10), to find a 
basis for more adequately tailored rehabilitation programs in order to improve the treatment 
effects for both high-risk subgroups and for those with good prognoses. The need for more 
knowledge in the area has received attention due to IMPR being expensive and time-consuming 
(44).  
 
2.4 THE CONCEPT OF EVIDENCE 
The Swedish National Board of Health and Welfare (Swe: Socialstyrelsen) recommends that 
healthcare professionals use their evidence-based practice model. In this model, the choice of 
treatment is based on four cornerstones. First, one must reflect on the patient’s clinical and 
physical circumstances as a start to find out what treatment options are available and what are 
not. Secondly, the selected treatment option should be strengthened by research evidence 
concerning its efficacy, effectiveness, and efficiency. Thirdly, if each treatment option is 
equally effective, the clinician must consider the patient’s preferences and likely actions (in 
terms of what interventions she or he is ready and able to accept). Finally, it is necessary that 
clinical expertise is available, i.e. including both the clinician’s knowledge and skills and the 
available resources in the health care system (66). While the first, third, and fourth pillar are 
very patient-specific, the second pillar is based on research evidence from scientific literature.  
 
2.4.1 Research evidence through systematic reviews 
Randomized controlled trials (RCTs) and pragmatic RCTs have been used as a golden standard 
to answer research questions regarding the efficacy and effectiveness of interventions, and 
since RCTs use the preferred methodology for causal inferences and due to randomization, 
they have the possibility to avoid confounding effects when comparing different treatment 
approaches. However, decisions about the usefulness of an intervention (or other types of 
research question) evidently cannot be based on the results of a single study – the evidence is 
too limited. Therefore, evidence synthesis is commonly based on systematic reviews of original 
studies, including RCTs as well as well-designed cohort studies, case-control studies, and 
sometimes even cross-sectional studies and pilot-studies(67). 
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In systematic reviews , a first step is to review the available literature narratively (or 
qualitatively), but this process is somewhat subjective since different experts can come to 
different conclusions, making drawing robust conclusions on the effectiveness of an 
intervention problematic when included studies are under-powered or contradictory. Re-
analysis of data though meta-analyses , which use the quantitative aggregation of all data 
available, can instead increase power and make effects or associations apparent and objective.  
Therefore, systematic reviews and meta-analyses are set on the top of the pyramid of evidence 
in evidence-based practice. In these processes, however, there is still a need to critically assess 
and judge the methodological quality of the studies they include. This process is called a Risk 
of Bias (RoB) assessment and there are several different tools developed for this purpose. 
 Assessment of Risk of Bias 
Many systematic reviews and meta-analyses focus on synthesizing the results from RCTs, 
comparing outcomes from different interventions. However, comparisons are difficult to make 
when methodological issues such as attrition, response rate, intervention dosage, outcome 
measure, soundness of statistical methods, the internal and external validity, etc., differ between 
the included studies. There are several specific RoB tools for identifying methodological 
weaknesses in order to distinguish between studies with high risk of bias and studies with low 
risk of bias. In other types of studies, e.g. observational, cohort, or register studies, which are 
non-randomized prognostic studies, evidence could be provided by within-group comparisons 
on real-world data, which may give higher external validity. These studies are referred to as 
effectiveness studies, and require other types of RoB tools (68). For prognostic studies, a 
special RoB tool has recently been developed,  and this tool has been suggested as a core tool 
in the performance of Cochrane review studies (69).  
Since conclusions of the outcome of a systematic review or meta-analysis study are based on 
the methodological quality of the included studies, it is important that the RoB assessment itself 
is well performed and of high scientific quality. Therefore, in the most robustly designed 
systematic review and meta-analysis studies, two or more researchers will perform an RoB 
assessment independently from each other, after which they will discuss each study to reach a 
consensus on its methodological quality; i.e. if it has a high, medium, or low RoB. Hence, this 
important step in evidence synthesis is based on both the researchers’ judgment and the 
instruments’ ability to provide a clear basis for judgment, both of which may contribute to a 
potential ‘measurement error’. Applying any measurement instruments also requires some 
evaluation of its measurement ability, here both referring to the researcher rating the instrument 
and the instrument itself. In this process, a calculation of the inter-rater agreement indicates 
aspects of reliability. 
 Grading of Recommendations, Assessment, Development and Evaluation, GRADE  
As a final step to reach levels of evidence a GRADE is performed. The GRADE process aims 
to define the “extent to which one can be confident that the estimate of effect or association is 
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correct”. It is a method that is used globally and that provides accurate estimates on specific 
outcomes that may be applied to recommendations for health care (70).  
GRADE has four levels of evidence, ranging from “very low” (+) to “high” (++++). Depending 
on the research designs upon which the synthesis is based, the starting point is either regarded 
as being high quality, such as evidence from RCTs, while other less inferential designs are 
rated as being lower quality. From this initial point, evidence levels can be downgraded due to 
factors that may decrease confidence in the estimates, such as a high RoB or publication bias. 
Evidence levels can also be upgraded due to factors such as large magnitudes of effect.  
 
2.4.2 Practice-based evidence  
Although available evidence supports the effectiveness of IMPR, the body of evidence risks 
also being based on certain reports reflecting artificial situations with regard to selected 
patients, risk for researcher allegiance, and problems with practical applications. RCTs provide 
the foundation of clinical evidence to guide clinicians in their selection of treatment options, 
however, these trials have known limitations, including not only the immense costs associated 
with the implementation of adequately powered studies, but also limited generalizability to 
naturalistic practice settings with a consecutive non-selective flow of patients with no extra 
“RCT-resources” or specialists, commonly available in RCT trials (49). A necessary step is 
therefore to investigate whether the evidence reported in RCTs as well as systematic reviews 
also holds for a consecutive non-selective flow of patients in real-world practice settings.  
Research methodology known as practice-based evidence evaluates the effectiveness of 
regimen programs through prospective observational cohort study designs, applied in 
rehabilitation research (71). The external validity in such designs is usually high because they 
include virtually all patients and potential confounders that could alter treatment responses (71). 
The methodology has certain characteristics (e.g. large sample sizes and multiple data sampling 
sites). Hence, both practice-based evidence and data gained through RCTs (or evidence-based 
practice) can be perceived as important complementary parts of an on-going translational 
“bench-to-bedside” research process to improve the outcomes of treatments for patients with 
chronic pain.  
Pragmatic clinical registry-studies can be a powerful and highly cost-effective method of 
establishing clinical evidence of national relevance in areas that might otherwise be difficult to 
evaluate, such as rehabilitation research (71). Analysis on prospective quality registries 
commonly reflects regular clinical settings, and carries the additional advantage of not 
requiring a wait of several years to gauge long-term effects. Also, further openings for large 
observational databases have received increasing scientific interest, applying techniques to 
emulate a target trial for comparative effectiveness, when a randomized trial is not feasible 
(72). By identifying data that represents independent groups (e.g. short vs. extensive IMPR 
duration) in a large, clinical registry-cohort with consecutive enrolment, it is believed that 
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important features of a prospective randomized trial can be combined with the inclusiveness 
and efficiencies of a large-scale nationwide clinical registry.  
2.4.3 Swedish National Quality Registries 
The Scandinavian countries, including Sweden, have a tradition of keeping a high number of 
well-established national registries that provide unique opportunities to perform register-based 
research that can be linked to individual national registration numbers – personal identification 
numbers that every citizen has (73, 74). In addition to population-based registries run by central 
authorities, there is also a great amount of registries appointed for quality assessment of the 
healthcare system; Swedish National Quality Registries (75). Their data is collected in real 
time, i.e. prospectively, and integrated into clinical workflows. A group of dedicated 
stakeholders representing health care, patient, and research perspectives are jointly responsible 
for developing these registries.  
Presently, about 100 National Quality Registries provide the Swedish healthcare system with 
a unique opportunity to monitor the quality of interventions and their results. Quality registries 
provide data that can be used in the evaluation of specific areas of healthcare, for instance heart 
disease, cancer, rheumatic diseases, etc. and include individualized data on patient problems, 
treatment, and outcomes usually followed over time. One of these is the Swedish Quality 
Registry for Pain Rehabilitation (SQRP).  
 Swedish Quality Registry for Pain Rehabilitation (SQRP) 
The SQRP is a quality register that was founded in 1998 with its main aim being to promote 
research and development in the field of IMPR (76). The registry includes data from patients 
with chronic non-malignant pain, who undergo an evaluation for specialist pain management. 
A growing number of clinical units all over Sweden are linked to the registry and in 2017, about 
40 specialist care units were included, giving it a coverage rate of 95% (geographic location is 
shown in Figure 2. Hence, the vast majority of patients in Sweden undergoing pain specialist 
care on tertiary level are included in SQRP. Every year, approximately 7000 new patients are 
added, representing at total of over 55,000 clinical visits (76). Recently, the SQRP was 
extended to include primary care units specializing in IMPR, where patients with less severe 
pain conditions and a lower psychological distress burden attend (77). 
SQRP is based primarily on patient-reported health data of core outcome domains suggested 
by the IMMPACT for chronic pain studies (55) and the Validation and Application of a patient 
relevant core outcome set to assess effectiveness of multimodal PAIN therapy (VAPAIN) 
consensus statement (78), i.e. pain, physical and emotional functioning, quality of life. Data is 
collected using established questionnaires, both generic and disease specific, prior to and 
directly after treatment as well as after a one-year follow-up period. There is a minimum set of 
established PROMs that are used by all clinics, but these can be complemented with additional 
measures of the clinics’ own preferences. Furthermore, data on diagnoses, socio-demographic 
details, information on employment, and sick leave status, as well as pain duration and future 
prospects, are collected.  
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The clinics, which routinely use the measures for the purpose of assessing individual patients, 
manually register data into the database of SQRP, provided they have the patient’s permission. 
The general aim of SQRP is to compare patient groups at different rehabilitation clinics and 
the effect of rehabilitation programs according to patient-reported outcome measures 
concerning function, activity, quality of life, and participation in working life and leisure (75). 
The registry enables detailed analyses for evaluation of effectiveness and quality of care, and, 
through rigorous regulatory (and ethical) processes, data can also be linked to the Swedish 
Social Insurance Agency and other registries. Annual summary reports are provided from the 
SQRP and the database is also subject to large empirical research projects which are preceded 
by application processes with valid ethical permits. 
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2.5 RATIONALE FOR THESIS 
Chronic musculoskeletal pain conditions constitute a major challenge for health care systems 
worldwide. Therapeutically, the necessity of a biopsychosocial approach using 
interdisciplinary rehabilitation is widely accepted – yet its effectiveness on several health 
outcomes continues to be only moderate. An important question is why do some patients 
undertaking IMPR improve, while others do not? What are their characteristics – is there any 
early information available from our national registries or from existing literature that can 
indicate how specific groups of patients will function after their rehabilitation? Regarding 
existing literature, a thorough evaluation of study quality of the studies upon which the 
evidence will be based is essential in systematic reviews and evidence synthesis. For the 
assessment of quality in prognosis studies, a new instrument that necessitates the evaluation of 
its reliability and functionality within this research topic has been introduced. What we know, 
however, is that existing evidence is inconclusive – and this hinders informed clinical decisions 
and the further development of IMPR. Clearly, many patients need support in managing pain 
and behavioral change that will lead to a healthier and more active life, but for how long do 
they need this support in organized IMRP? In Sweden, specialist IMPR programs range 
between four and 18 (or more) weeks in duration, and are often based on local tradition and 
medical staff preferences. As indicated, IMPR duration (one aspect of dosage) is certainly 
complex and cannot be directly transferred from pharmacotherapeutic principles. This topic 
has been extensively discussed in pain rehabilitation networks and patient associations and has 
been acknowledged in the latest SBU report on pain rehabilitation. Through the latest data in 
SQRP, now also including data on treatment duration, this thesis had the unique possibility to 
challenge the idea that “behavioral change takes time” by contrasting effects of IMPR duration 
on health-related outcomes. To the best of our knowledge, this is the first study of its kind that 
has a broad national representativeness.  
Hence, the rationale for the present thesis was to provide updated evidence, that has been called 
for both nationally and internationally, on prognostic factors and the effectiveness of IMPR 
duration, in order to tackle the contemporary challenges with this major patient group.   
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3 AIMS 
Given the existing gaps in knowledge, the overall aim was to meta-synthesize existing evidence 
on prognosis for a positive IMPR outcome, and to investigate the reliability and functionality 
of a new tool for RoB assessment that can be used in systematic reviews; the Quality in 
Prognosis Studies (QUIPS) tool. A further aim was to delineate the prognostic factors and 
effectiveness of IMPR, on dimensions of health-related quality of life by approaching large-
scale nationwide data in patients with chronic pain receiving rehabilitation.  
 
3.1 SPECIFIC AIMS 
 
The specific aims of the studies included in the thesis were: 
 to identify, evaluate, and meta-synthesize published data on prognostic factors, 
focusing on pain and physical and emotional functioning, for long-term follow-up 
physical functioning in patients with chronic pain (Study I) 
 
 to determine the interrater agreement of the risk of bias assessment in prognostic 
studies using the instrument Quality in Prognosis Studies (QUIPS) and to elaborate on 
the use of this instrument,    (Study II) 
 
 to investigate prognostic factors for long-term physical and emotional functioning by 
targeting patients’ baseline characteristics and health measures, (Study III) 
 
 to evaluate the effectiveness of IMPR on physical and emotional functioning, pain, 
anxiety and depression, and perceived health, at post-intervention and at 12 months 
after intervention, and    (Study IV) 
 
 to evaluate the comparative effectiveness between IMPR of short, moderate and long 
duration on these outcomes.    (Study IV) 
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4 METHODS 
4.1 STUDY DESIGNS 
Four studies are included in the thesis. Study I is a systematic review and meta-analysis of 
original international reports with a prospective study design. Study II is a methodological 
study, on inter-rater agreement. Studies III and IV are of prospective, large-scale multicenter, 
observational designs; Study III focuses on prognosis and Study IV on IMPR effectiveness. 
Study design, participants, data sources, and analyses are summarized in Table I.  
 
Table I. Overview of study design, participants, data sources and analyses of the included studies. 
 
Study I Study II Study III Study IV 
Design Systematic Review 
with meta-analysis 
Inter-rater-agreement 
(reliability) 
 
Pragmatic longitudinal 
multicentre register-
based study. 
 
Pragmatic longitudinal 
multicentre register-
based controlled study. 
 
Material/ 
Participants 
25 original research 
reports, published 
1983-2016 
n= 9436 
2 independent raters  
43 research reports 
 
38 specialist clinics 
n=2876, 
complete cases: 
baseline and 12 month 
follow-up after IMPR 
15 specialist clinics 
n=2413, 
baseline, post and 12 
month follow-up after 
IMPR 
Data sources Medline, Embase, PsychINFO, CINAHL,  
Web of Science, Cochrane CENTRAL 
Swedish Quality Registry for Pain Rehabilitation 
Analysis Narrative and 
Quantitative meta-
synthesis 
Grading of Level of 
Evidence 
Cohen’s quadratic 
weighted kappa 
coefficient 
PCA for dependent 
variables 
Logistic regression 
GEE- within/between 
group analyses 
Proportion change one 
MCID 
GEE: Generalized estimating equation, IMPR: Interdisciplinary multimodal pain rehabilitation, MCID: Minimal 
clinical important difference, PCA: Principal component analysis 
 
4.2 ETHICS APPROVAL 
Studies I and II. Analyses were based on already published data included in systematic reviews 
of original studies (Study I) and resulting data from Risk of Bias rating performed by the authors 
themselves as part of processing the systematic review material (Study II). There were therefore 
no personal data or data of sensitive nature generated in this review project, hence no study-
specific ethical permission was required for Studies I-II. The protocol is registered in the 
International Prospective Register of Systematic Reviews (PROSPERO) id: 
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CRD42016025339, and a study protocol presenting the design and planned evidence work was 
published in advance of the main study (79). 
Studies III and IV. These studies constitute part of a Swedish national project involving original 
nationwide registry data from the SQRP. The project has been granted ethical approval 
(Etikprövningsnämnden Stockholm, dnr: 2013/1842-31/2) (covering Studies III-IV) and the 
protocol is registered at Clinical Trials.gov (id: NCT02248363). All data for the purposes of 
the present project was made anonymous by statisticians at SQRP before exporting it, hence 
no identifiable personal information was included when data is received by the project group. 
Furthermore, analysis and presentation of the data are only conducted at group level and hence 
not possible to identify specific individuals by such analysis/presentation.  
 
4.3 PARTICIPANTS AND SETTINGS 
The study population in this thesis consists of working-age adults with chronic musculoskeletal 
pain for a duration of over three months, not emanating from malignancies or systemic diseases, 
e.g. back or neck pain, generalized pain syndromes, fibromyalgia, and general widespread pain, 
who have taken part in IMPR. Table II shows countries from which patients were recruited, 
and the patient characteristics age, sex, and pain duration for Studies I – IV.  
 
Table II: Country, sex, age, mean pain duration (SD or range) of the included patients in the thesis 
(Studies I -IV). 
 Study I Study II Study III Study IV 
Geographical 
origins/country 
Europe (19), North 
America (5), New 
Zealand (1)  
N.A.** Sweden Sweden 
Sex, women% 60%* N.A. 77% 80% 
Age, years (SD) 43 (10.4) N.A. 43.5 (10.7) 41.3 (10.7) 
Pain duration, mean 
(range)  
3 months-  > 10 
years 
N.A. 106 months 
66 median 
79 months 
SD: Standard deviation *For Study I, the proportion of females was calculated from the information available 
from all included studies, and for pain duration, the mean and range of the included studies was calculated. 
**Study II is based only on material derived from the Risk of Bias ratings of included articles, not the reported 
patient data.  
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As relevant for Studies III – IV, Figure 2 illustrates the geographical distribution of specialist 
IMRP clinics in Sweden in relation to population density (all 38 clinics marked were included 
in Study III, while 15 of these clinics were included in Study IV). 
 
Figure 2.   IMPR clinics in Sweden, linked to SQRP and population density. 
 
4.4 INTERVENTION 
In Studies I-II, our inclusion criteria was participation in any multidisciplinary, interdisciplinary 
or multimodal rehabilitation, with a biopsychosocial treatment approach, coordinated by ≥3 
different health professionals where a shared collaboration was explicitly expressed. Health 
professionals involved were commonly a physician, a physiotherapist and a psychologist, with 
a social worker or occupational therapist on occasion. IMPR (in these studies referred to as 
MDR) could be of any duration/intensity and rehabilitation approach, in either inpatient or 
outpatient settings. IMPR-program duration commonly lasted between two to eight weeks, 
with nearly half of the studies reporting an IMPR duration of four to eight weeks. The 
remaining studies reported a duration exceeding eight weeks. Some programs included two 
phases, with a follow-up period with prolonged rehabilitation time. IMPR was either delivered 
as full-time treatment over a period of a couple of weeks, or part-time treatment over a couple 
of months. 
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In Sweden, the definition for IMPR is basically identical to the criteria given for Studies I-II 
above. Specifically, Swedish national medical guidelines for IMPR for chronic pain define it 
as treatment with an interdisciplinary team specializing in pain management, consisting of at 
least three professions; a physician specializing in rehabilitation medicine, a physiotherapist, a 
social worker, and a psychologist, plus an occupational therapist if needed (23). Commonly, 
IMPR is scheduled as a group-based program, with groups usually consisting of six to eight 
participants. It is emphasized that within these groups, each patient has an individual plan, 
schedule, and contacts, according to the patient’s own goal setting. IMPR programs typically 
last about 10 weeks, but range between 4-18 weeks, with treatment delivered 1-5 days/week, 
in half or full days, for 8-40 hours/week.  Some programs run continuously with face-to-face 
meetings, while others are delivered with an initiation phase, a self-management phase, and a 
completion or booster phase.  
4.5 OUTCOMES 
In order to measure general functioning and the impact of chronic pain on more general life 
concepts the Short Form Health Survey (SF-36) was used as a main outcome measure. The SF-
36 is a self-assessed multi-purpose short-form health survey with 36 questions reflecting 
health-related quality of life. The 36 included questions yield an 8-scale profile of functional 
health and wellbeing scores, which can be incorporated into the psychometrically-based 
physical and mental health summary measures; SF-36 Physical Component Summary (SF-36 
PCS) and SF-36 Mental Component Summary (SF-36 MCS). These two summary measures 
of SF-36, both ranging from 0-100, were used as dependent measures of physical and mental 
functioning. The SF-36 has been proven useful in surveys of general and specific populations, 
for comparing the relative burden of diseases and in differentiating the health benefits produced 
by a wide range of different treatments (24). The outcomes in this thesis relate mainly to general 
physical and psychological functioning, and expand though more proximal to more distal 
disease impact concepts. For instance, the SF- 36, was used in its more proximal form in Study 
I, with the SF-36 subscale Physical functioning (PF), reflecting functioning from a more 
delimited level while in Study III the SF -36 Physical Component Summary was used as a 
reflection of general physical health and functioning, the same applied for the equivalent SF-
36 Mental Component Summary. If looking at these two component summaries in tandem they 
can apply as measures of more distal general concepts such as HRQoL. By using the summary 
scores of SF-35 PCS and MCS, our outcomes are thus closer related to concepts of general 
functioning. In Study IV we also evaluated an array of measures, covering a bio-psycho-social 
spectra, and at the same time core, to proximal-distal disease impact concepts. All of these 
constitute the mandatory measures in SQRP. 
For a graphical illustration according to Schematic diagram depicting the outcome measures 
used in Studies I and III-IV – and their main position on subdomains of proximal-distal 
concepts of functioning see Figure 3, and for further details, see below:  
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The patient’s reported pain intensity for the last week (7 days) was quantified with the Numeric 
Rating Scale (NRS), administered by asking the patient to estimate his or her pain on a scale 
of 0 to 10, with 0 representing no pain and 10 representing the worst possible pain (25) 
Perceived health status was assessed using the EuroQol-5 dimensions (EQ-5D). This is a self-
assessed standardized measure that provides a simple, generic measure of health for clinical 
and economic appraisal. It is applicable to a wide range of health conditions and treatments and 
it provides a single index value for health status (where a score of 1 represents good health and 
-0.564 “worse than death” that can be used in clinical and economic evaluations of health care 
as well as in population health surveys (26).  
Further, and more specific to the experience of chronic pain, dimensions of pain intensity, 
emotional distress, cognitive and functional adaptation, and social support were assessed using 
the Multidimensional Pain Inventory (MPI) (27). In accordance with the procedure described 
by McKillop et al., two summary scores were used for the presentation of domain impairment 
and social support, MPI Impairment (0-6, where high scores represent high perceived 
impairment) and MPI Social support (0-6, where high scores represent high social support) 
(28).  
Finally, symptoms of anxiety and depression in patients with somatic diseases were assessed 
using the Hospital Anxiety and Depression Scale (HADS), which is a widely used patient self-
rated scale with 14 questions; 7 addressing "anxiety" and 7 addressing "depression" (subscales; 
HADS-A – anxiety and HADS-D – depression) that each ranges from 0-21 (in total 0-42) (29). 
Study II did not include any patient reported measures, outcome was instead the degree of inter-
rater agreement, as assessed with Cohen’s weighted kappa. For more specific study 
operationalization, see details reported in sections below.  
Figure 3. Presentation of outcome measures used in Study I and III-IV - and their main position on 
subdomains of proximal- distal concepts of functioning (56). Dark blue represents main outcomes, light blue 
represents secondary outcomes 
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4.6 STUDY I 
4.6.1 Data sources and Material 
For the purpose of identifying original studies of relevance, electronic searches were performed 
in six databases of major relevance for the topic: MEDLINE (via Ovid), EMBASE (via 
Elsevier), PsycINFO (via Ovid), CINAHL (via EBSCO), Web of Science (via Thomson 
Reuters), and the Cochrane Central Register of Controlled Trials (CENTRAL). Searches 
covered the publication period January 1980 to April 2017.  
A total of 25 original studies published between 1983 and 2016 were included in the study, all 
of which investigated and reported data on prognostic factors for physical functioning after 
IMPR. Included studies were conducted in Europe (19), North America (5), and New Zealand 
(1), with a total study population of 9436 participants taking part in IMPR. 
 
4.6.2 Procedures 
Study I constitutes the first part in a project entitled “Predictors of multidisciplinary 
rehabilitation outcomes in patients with chronic musculoskeletal pain”, and focused on 
physical function – one of four targeted outcomes. For further details please refer to our 
published study protocol (79). The systematic literature review and meta-analysis was 
conducted according to the following four main steps, as recommended (80, 81). 
1) Study selection, 
2) Assessment of study quality (QUIPS), 
3) Narrative and quantitative synthesis, 
4) Grading of the levels of evidence (GRADE). 
 Study selection 
The study selection process was performed using the Covidence online systematic review 
software (82): screening of titles, screening of title/abstract, screening of full texts, and a final 
screening of study relevance, subsequently excluding studies revealing non-eligibility criteria. 
Figure 4, The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) Flow Diagram (83), shows the study selection process and the number of papers 
included in the different stages of the systematic review.  
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Figure 4. PRISMA Flow Diagram illustrating systematic review process, and Study I and Study II 
material. (84) PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
Tseli et al. Clin J Pain 2019 35(2):148-173, modified under the Creative Commons Attribution License 4.0. 
 
A multidisciplinary review team, consisting of six members (two physicians specializing in 
rehabilitation medicine, one psychologist, and three physiotherapists), performed the screening 
and RoB assessments, independently and two by two. A randomization scheme was used to 
distribute studies in two evaluation trails, each with a set of independent reviewers. For more 
details please refer to study protocol (79). 
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 Study quality 
The studies that fulfilled the eligibility and relevance criteria were assessed using the Quality 
in Prognostic Studies (QUIPS) tool (69) to evaluate the Risk of Bias (RoB). All studies were 
rated on a three-point scale: “low”, “moderate”, or “high” RoB.  
 Narrative and quantitative synthesis 
In the part of the study that focused on prognostic factors for physical functioning, papers with 
this specific outcome were selected (n= 25). Data from every study qualifying for inclusion in 
the present study were extracted into a coding file which provided the material for narrative 
and quantitative syntheses. In the narrative analysis, the results of each prognostic factor in 
relation to outcome physical functioning were scored with + or -, indicating the direction of a 
statistical significant association between the prognostic factor and the outcome. Those 
prognostic factors that did not reach statistical relevance were identified with a zero.  
After the narrative synthesis, a more specific evaluation of statistical outcomes of prognostic 
data was carried out by performing a meta-analysis. Effect sizes from single prognostic factors 
were computed and transformed when necessary into a common index, odds ratio (OR), and 
95% confidence interval (CI). The variance-weighted pooled ORs were then computed through 
a random effects meta-analysis using the software Review Manager (85). Heterogeneity was 
assessed, and funnel plots and sensitivity analyses were performed accordingly (86).  
 Grading the evidence 
For the evidence synthesis, the analyzed prognostic factors were evaluated with the GRADE 
method, judging the confidence in the effect estimate of the prognostic factor on a four-point 
scale, including “very low”, “low”, “moderate”, and “high” level of evidence (87, 88). In 
agreement with previous reporting on adaptation of GRADE in prognostic studies (88), the 
initial level of evidence was set at high quality and certainty the evidence was thereafter 
assessed based on the remaining eight criteria; RoB, imprecision, inconsistency, indirectness, 
and publication bias (decreasing evidence level) and large magnitudes of effect, dose-response 
gradients, and the lack of confounding (increasing evidence level). 
 
4.6.3 Assessments 
The dependent variable Physical functioning was assessed primarily through self-reports, for 
example using the Short Form 36-item Health Survey (SF-36), Roland-Morris Disability 
Questionnaire (RMDQ), or the Oswestry Disability Inventory (ODI). Included measures were 
generic or disease-specific, targeting functioning or, the opposite, i.e. disability. Included 
measures extended across proximal and distal impact concepts, see Figure 3 for a description 
of measures. 
The independent variables: Measures of investigated potential prognostic factors were collated 
into relevant assessment domains; Pain-related factors, Physical function-related factors, and 
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Psychological factors. For each domain, the included measures were further partitioned into 
seven subdomains before synthesis, each representing a prognostic factor: Pain intensity, Pain 
duration, Self-reported physical function, Performance-based physical function, Emotional 
distress, Cognitive Behavioral ‘Protective’ factors (positive direction), and Cognitive 
Behavioral ‘Risk’ factors (negative direction). A detailed description of included measures 
within each prognostic factor is given in Study I.  
 
4.7 STUDY II 
4.7.1 Material 
The 105 studies retrieved from the systematic search as described in the study protocol (79) 
and Study I formed the base of Study II. The studies that were evaluated for RoB by the two 
experienced raters independently during the systematic review process were analyzed for inter-
rater reliability; this included a total of 43 papers, 10 of which pertained to the outcome Physical 
functioning (Study I) and an additional 34 pertaining to other outcomes, i.e. pain, work and 
quality of life. 
 
4.7.2 Procedures 
To assess the RoB in the studies selected for inclusion, a new tool, the Quality In Prognosis 
Studies (QUIPS) was used. QUIPS, developed for quality assessment in prognostic studies, 
consists of six domains; 1) Study participation, 2) Study attrition, 3) Prognostic factor 
measurement, 4) Outcome measurement, 5) Study confounding, and 6) Statistical analysis and 
reporting – and these are rated on a three-point scale with low, moderate, or high RoB. Each 
domain has 3-7 corresponding prompting items, to be answered on a four-point scale (yes, 
partial, no, unsure). These are intended to provide a basis for judgment on RoB for the domain 
in question (69). For every specific use of the instrument, a key list is required, which was 
created by the raters before the initiation of the quality assessment, and suggestions on how to 
create this were provided by the instrument developer through personal communication. 
In order to become familiar with the quality assessment process, some studies were strategically 
selected for a common discussion on ratings. Thereafter, a first round of RoB assessment was 
performed independently (n=15) and the results were discussed in order to reach consensus. 
The remaining studies were then assessed, again independently, in a second round (n=28) and 
conflicts were resolved as they were previously.  
After completion of the RoB assessment, evaluation of the inter-rater agreement was performed 
using Cohen’s quadratic weighted kappa coefficient of both the total number of studies and for 
round 1 and 2 separately. As a final step, the authors discussed the results and elaborated on 
the functionality of the tool, highlighting the difficulties and strengths of the tool to aid future 
studies using QUIPS. 
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4.8 STUDY III 
4.8.1 Data source and Material 
The SQRP provided data, and the present study was based on 38 specialist care clinics across 
Sweden, including 2,876 patients who both participated in an IMPR program during the period 
2012 - 2014 and took part in the 12-month follow-up. The geographical distribution of these 
clinics included all parts of Sweden, and was proportional to population. Further details 
regarding study procedures are given in Study III. 
 
4.8.2 Dependent and independent variables 
Dependent outcome variables were defined using Principal Component Analysis (PCA). Our 
PCA with orthogonal rotation emerged with two distinct components, relating to Physical 
functioning based on the SF-36 PCS solely, and Emotional functioning based on SF-36 MCS, 
HADS-A, and HADS-D respectively, hence reflecting a general perspective on functioning 
and HRQoL. To create binominal outcomes, we used the Minimal Clinical Important 
Difference (MCID) as cut-off, for a definition of improvement on our dependent outcomes. An 
increase of ≥3 on SF-36 PCS was chosen as a MCID for Physical functioning, and for 
Emotional functioning, the preconditions were an increase of ≥3 on SF-36 MCS and a decrease 
of ≥1.5 on either HADS-D or HADS-A.  
Regarding independent variables, there were 18 baseline regressors (potential prognostic 
factors) used in the initial regression analyses. The variables represented socio-demographic, 
pain-related, and other multidimensional health descriptors, a detailed description of included 
independent variables is given in Study III. A theoretical and empirical reasoning (89) preceded 
the selection of these baseline regressors (89), which were then entered in univariate and 
multivariable analyses. 
 
4.9 STUDY IV 
4.9.1 Data source and Material 
The SQRP again provided data, and Study IV was based on data from 15 specialist care clinics 
across Sweden. It included 2,413 patients who both participated in an IMPR program during 
the period 2012 - 2014 and were followed through post-intervention and 12-month follow-up. 
The reason for including 15 clinics was based on the intention to have reliable data for the 
assessment of comparative effectiveness of treatment duration. Here, as a complement to new 
and previously untested register data on the duration of IMPR, a crosscheck validation was 
carried out for data of relevance (representing 2012 - 2014), using independent, empirical 
information from clinic representatives. This yielded 15 clinical settings for which baseline 
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data and PROMs were extracted for analysis. The geographical distribution of these 15 clinics 
included all parts of Sweden, was again proportional to population, and the range of program 
duration was also equally dispersed. Further details regarding study procedures is given in 
Study IV. 
4.9.2 Dependent and independent variables 
Primary outcomes were Physical and Emotional functioning, based on the psychometrically-
based physical and mental health summary of Short Form 36-item Health Survey; SF-36 PCS 
and SF-36 MCS, representing core domains of HRQoL (5). Secondary outcomes were Pain 
intensity (NRS), two summary scales derived from the Multidimensional Pain Inventory 
(MPI); perceived impairment and perceived social support, HADS, and Perceived health (EQ-
5D). Effectiveness within and between groups was evaluated in two ways, estimating the 
marginal effects using Generalized estimating equation (GEE), and by calculating percentage 
attaining a MCID. The MCID was used as cut-off for a definition of improvement on our 
dependent outcomes. The MCID was also used in the opposite direction, reverting the same 
cut off as an indicator of possible deterioration on our dependent outcomes. Hence three 
possible outcome categories were identified on the presented MCID; improved, no change, and 
deteriorated. Further details on scale range, direction, and MCID-definitions of included 
outcome measures are presented in Table III. 
Table III. Patient-reported outcome measures and MCID-definitions 
 Subscale  Scale range What is 
‘better’  
MCID-levels Reference 
Primary outcome measure     
Short Form 36-item 
Health Survey (SF-36) 
Physical 
Component 
Summary 
0-100 ↑ ≥3 (90, 91) 
 Mental 
Component 
Summary 
0-100 ↑ ≥3  
Secondary outcome measures     
Numeric Rating Scale 
(NRS) 
 0-10 ↓ ≥ 2 (92, 93) 
Multidimensional Pain 
Inventory (MPI) (94) 
Impairment 
summary scale 
0-6 ↓ ≥ 0.6 (95) 
 Social support 
summary scale 
0-6 ↑ ≥ 0.6  
Hospital Anxiety and 
Depression Scale 
HADS Anxiety 0-21 ↓ ≥1.5 (96) 
 HADS 
Depression 
0-21 ↓ ≥1.5  
European Quality of 
Life instrument (EQ-
5D) 
EQ-5D index -0,564-1 ↑ ≥ 0.1 (97) 
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Independent variable: IMPR duration (weeks). For the categorization of the variable, clinics 
were divided into three delimited and pragmatic groups of different program duration, intended 
to reflect current diversity of applied IMPR: short (4-9 weeks; 7 clinics), moderate (10 weeks; 
3 clinics), and long (11-18 weeks; 5 clinics). 
 
4.10 STATISTICAL ANALYSES  
The statistical analyses used in this thesis are presented in Table IV. For details on statistics, 
see Supplementary Study I – IV. Table IV shows statistical analyses used in this thesis. 
Table IV. Statistical analyses used in this thesis. 
Statistics 
 
Study I Study II Study III Study IV 
Descriptive 
    
Frequency (n), percentage (%) x x x x 
Mean/median (SD/range) x 
 
x x 
Effect size calculation, and conversion to common 
index: Odds Ratio 
x 
   
Inferential 
    
Cohen’s kappa x x 
  
Meta-analysis  x 
   
Funnel plots x 
   
Pearson's correlation coefficient 
  
x x 
Principal Component Analysis 
  
x 
 
Minimal Clinical Important Difference  
  
x x 
Logistic regression 
  
x 
 
Generalized estimating equation ( GEE) 
   
x 
 
4.10.1 Study I 
The strength of the relationship between a specific prognostic factor and corresponding 
outcome was quantified using the specific commonly-used procedures as descripted by Lipsey 
(98). In short, the statistical outcomes (effect sizes) from single prognostic factors were with 
the help of online calculators converted into a common index of variance-weighed ORs to 
permit pooling across studies (86, 99, 100). For each prognostic factor, the software Review 
Manager (85) was used to compute variance weighted pooled ORs and 95% confidence 
intervals (CI) in a random effects model. The generic inverse variance method was used, since 
this method permits a wide selection of data formats in the analyses (101). Measures of 
statistical heterogeneity were calculated (e.g. I2), and funnel plots were used to assess potential 
publication bias (86, 99, 100).  
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4.10.2 Study II 
The inter-rater agreement was investigated to determine the consistency between the two 
experienced senior raters using all domains from all papers (n=43) that were assessed by these 
raters. The raters judged the papers separately using the QUIPS three-graded RoB scores 
(”low”, ”moderate”, or ”high” RoB). When the two raters scored alike on a domain, this was 
considered as an “agreement”, while “maximal disagreement” was defined as one rater scoring 
low RoB and the other scoring high RoB. All other cases of disagreement were defined as 
partial disagreement. The percentage of the number of domains judged alike by the two raters 
divided by the total number of domains (n= 258; i.e. 43 papers × 6 domains) before reaching 
consensus was calculated as a rate of agreement across all papers. This was also calculated for 
separately for the first and second rounds (n= 90 and n= 168, respectively). An online kappa 
calculator was used to calculate Cohen’s kappa (κ) with quadratic weighting (102) as a measure 
of inter-rater reliability and the coefficient was interpreted as follows: κ= 0.00–0.20, no 
agreement; κ= 0.21–0.39, weak agreement; κ= 0.40–0.59, minimal agreement; κ= 0.60–0.79, 
moderate agreement; κ= 0.80–0.90, strong agreement; and κ> 0.90, almost perfect agreement. 
Moreover, we tested if there were any differences in overall agreement between the raters, 
between the different rounds, and between the papers with high and low RoB by using an online 
test of proportion calculator (103). 
4.10.3 Study III 
Binary logistic regression was initially used to quantify the univariate associations between 
baseline variables (regressors) and outcomes, and an inclusion criterion of p ≤0.2 was preferred 
for further analyses in multiple regression models. Regressors were examined for potential 
multicollinearity bias.  
Using a top-down approach, the final multiple regression model was identified in a 2-step 
procedure. Firstly, stepwise backwards elimination was used to eliminate variables based on 
the highest p-value, until only variables significant at p ≤ 0.2 remained. Secondly, in 
accordance with the purposeful selection process described by Hosmer, Lemeshow, and 
Sturdivant (34), variables already eliminated in the univariate analyses were included one by 
one in the multiple regression model and retained if they were significant at p < 0.05, yielding 
a preliminary final model with all variables significant at p ≤ 0.2. Baseline regressors 
significant at p < 0.05 in the final model were recognized as important prognostic factors.  
4.10.4 Study IV 
Regarding treatment effectiveness on duration, a repeated GEE with robust standard errors was 
used to compute the average within-subjects effect for the complete sample from baseline to 
rehabilitation end, and to one-year follow-up (104). Standardization was used to compute the 
marginal effects between the duration groups, based on a general linear model with robust 
standard errors (105). In our between-group analyses, IMPR duration (short vs. moderate vs. 
long) was used as a between-subject factor. Treatment days/weeks and baseline level in all 
defined outcomes were adjusted for in the GEE modeling. GEE handle missing data by 
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including all available data in the estimations. Alpha levels were set to p < 0.01 for all analysis 
stages. Our sample size of 2413 patients entailed high test-power for the analyses. Therefore, 
in addition to tests of statistical significance, all outcomes were dichotomised into patients who 
attained a MCID and patients who did not (106), in order to aid clinical interpretation. 
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5 RESULTS 
5.1 STUDY I 
A summary of findings, and overall quality as assessed with GRADE, is shown in Table VI. 
Results from the evidence synthesis on prognostic factors for physical functioning at ≥ 6 
months is presented for the three prognostic factor domains; Pain, Physical, and Psychological. 
Pain related factors: Pain intensity and pain duration were not associated with outcome. Here, 
the level of evidence was moderate due to inconsistency of the results. Physical factors: High 
self-reported physical functioning was associated with a positive outcome. The level of 
evidence was low, due to inconsistency of the results and study limitations, i.e. risk of bias. 
Performance-based physical factors, analyzed with narrative synthesis only, were not 
associated with outcome and there was no evidence of prognostic value. Psychological factors: 
Low levels of emotional distress (A), high levels of cognitive behavioral protective- factors 
(B)
, 
and low levels of cognitive behavioral risk-factors were associated with a positive outcome (C), 
see Figure 5. The level of evidence was moderate for all three psychological factor-groups.  
 
Figure 5. Forest plots for Psychological factors and their association with a positive outcome: A) 
emotional distress, B) cognitive behavioral risk factors, and C) cognitive behavioral protective factors 
(84).  
Tseli et al. Clin J Pain 2019 35(2):148-173. Reprinted under the Creative Commons Attribution License 4.0 (CCBY). 
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Table VI. Summary of findings and GRADE - level of evidence (84). 
 
Tseli et al. Clin J Pain 2019 35(2):148-173. Reprinted under the Creative Commons Attribution License 4.0 (CCBY). 
 
5.2 STUDY II 
The inter-rater agreement, when assessed for all domains and all included papers, was 
interpreted as “weak”, κ = 0.475 (95% CI = 0.4–0.6). Round 1 emerged with “Minimal 
agreement” κ = 0.323 (95% CI = 0.1–0.5), and Round 2 emerged with “weak agreement” κ = 
0.536 (95% CI = 0.4–0.7), indicating somewhat improved agreement after the conflicts/ 
consensus discussion following Round 1. Table VII shows inter-rater agreement in detail, for 
all rated papers and for the two rounds separately.  
 
Table VII. Inter-rater agreement for all rated papers and for the two rounds separately (107). 
 
Grooten et al. Diagnostic and Prognostic Research 2019 3:5. Reprinted under the Creative Commons Attribution License 4.0 (CCBY). 
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The degree of inter-rater agreement varied between the 6 assessed domains; the Kappa 
calculations showed minimal agreement for domains 1 “study participation”, 3 “prognostic 
factor measurement”, 4 “outcome measurement”, and 6 “statistical analysis and reporting”. 
They showed weak agreement for domain 5 “study confounding” and moderate agreement for 
domain 2 “study attrition”.  
Elaboration of the results and suggestions for improving the inter-rater agreement and 
functionality are presented in a BMC Blog Network (108) accessed by the following link: 
http://blogs.biomedcentral.com/on-medicine/2019/04/18/assessing-study-quality-bias-
prognosis-research-rehabilitation-chronic-pain-using-quips-tool/ 
 
5.3 STUDY III 
Multivariable logistic regression analyses revealed the significant (p ≤0.05) prognostic factors 
for improved Physical and Emotional functioning at 1-year follow-up after completion of an 
IMPR program – results are presented in text below and illustrated as forest plots in Figure 6.  
Physical functioning: Employment status and one’s beliefs in restored health were significant 
prognostic factors for improvement. Higher emotional functioning was also related, as were 
five additional variables: younger age, lower initial levels of pain intensity (NRS), pain-related 
interference in everyday life (MPI Pain interference), a lower level of physical functioning (SF-
36 PCS), and higher initial levels of anxiety (HAD- A). In the final model, the overall 
percentage of correctly classified cases was 64% and the explained variance 15%, Nagelkerke 
R Square, 0.151 (Cox & Snell R Square 0.114). Diagnostic tests of the final model indicated 
acceptable discrimination (AUC of 0.70, 95% CI: 0.68-0.71).  
Emotional functioning: Employment status proved again to be a prognostic factor for 
improvement. A lower level of emotional health (SF-36 MCS) emerged as related, as were 
three additional variables: a European origin, higher overall activity levels (MPI Overall 
activity), and higher sense of life control (MPI Life control). In this final model, the overall 
percentage of correctly classified cases was 67% and the explained variance 21%, Nagelkerke 
R Square, 0.210 (Cox & Snell R Square 0.157). Diagnostic tests of the final model indicated 
fair discrimination (AUC of 0.73 95%CI: 0.71- 0.75). 
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 Physical functioning  Emotional functioning 
Figure 6. Prognostic factors for Physical and Emotional functioning one year after IMPR. Forest plot 
showing baseline socio-demographic, pain- and health-related factors, and associations with positive 
outcome, at p ≤ 0.05. Categorical variables are shown with ORs for every category in comparison to 
reference category, and continuous variables are shown as “mean” OR for one step increase/decrease 
one range of specific measure (0-10, 0- 2I, 0-100).  For SF- 36 PCS, SF-36 MCS, MPI Life control, and 
MPI Overall activity high scores = better health, and for Pain intensity, MPI Pain interference, and HADS-
Anxiety high scores = worse health.  
 
5.4 STUDY IV 
In all, 2413 participants were referred to IMPR and completed an IMPR program at one of the 
15 specialist clinics. Of these, a total of 1889 (78%) completed the post-intervention follow-
up, and 1536 (64%) provided data at the 12-month follow-up. Analyses on baseline data 
revealed no clinically important differences between participants that provided data at the 12-
month follow-up vs. those missing. Personal characteristics for the three groups were similar. 
 
Effectiveness of IMPR – within-group analyses 
IMPR consistently proved to be clinically effective on our main outcomes; physical and mental 
health. Patients improved significantly post intervention (p < 0.01) and the effects were 
sustained at the 12-month follow-up. This result was also evident for our secondary outcomes; 
pain intensity (NRS), Impairment and Social support (MPI), Anxiety and Depression (HADS), 
and Perceived health (EQ-5D). Figure 7 shows means and 95% CI, respectively, of the course 
in physical and mental health (SF-36 PCS and SF-36 MCS) from baseline to 12-month follow-
up. 
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Figure 7. Change in HRQoL from baseline to post intervention and 12-month follow-up, measured using 
SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS). High values 
indicate better status. In the model, adjustment was made for baseline status and treatment days/week. 
Note: graphs show baseline values as they were, while statistical analyses were controlled for 
differences at baseline. The dotted line indicates the normal value for the general population 
 
Effectiveness of IMPR – between-group analyses 
There were no overall between-group effects; results showed that all groups, regardless of 
duration, had significant improvements in all outcomes, which were evident both post-
intervention and at the 12-month follow-up. It was notable, however, that there was a 
statistically significant (p = < 0.01), but clinically negligible, greater 12-month effect on 
physical health in the moderate duration program (SF-36 PCS=0.009) than there was in the 
short duration program. 
Despite the average effect being good, it emerged from our GEE-modeling that there was a 
noticeable proportion of patients who clinically deteriorated according to minimal clinical 
important difference (MCID) during the follow-up period. Here, regarding physical health, 
42% improved significantly post-intervention according to MCID, however, 23% deteriorated 
according to MCID. At 12-month follow-up, this was 45% and 22% respectively. Regarding 
mental health, the corresponding MCID for improvement/deterioration was 52%/26% post-
intervention and 50%/28% at the 12-month follow-up.  
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Figure 8 shows the proportion of patients attaining a change equivalent to a MCID at post-
intervention and 12-month follow-up, on primary and secondary outcomes. 
 
 
 
Figure 8. Minimal Clinically Important Difference (MCID) for primary and secondary outcomes at post-
intervention and 12-month follow-up. The positive bars (green) show the proportion of patients who 
improved. while the negative bars (red) show the proportion of patients who deteriorated. 
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6 DISCUSSION 
 
6.1 MAIN FINDINGS 
The research presented in this thesis focuses on building evidence to tackle the contemporary 
challenges associated with rehabilitation in this major patient group of people suffering from 
chronic pain conditions. The evidence synthesis of published original studies showed, with a 
low to moderate level of evidence, that patient characteristics relating to better initial physical 
and emotional functioning, with less negative and more positive coping strategies, positively 
influenced prognosis on long-term physical functioning. Pain level and duration of pain were 
not prognostic for the outcome, with a moderate level of evidence, indicating that life impact 
concepts of pain are more relevant than pain itself for the understanding of prognosticating 
future functioning.  
In the process of evidence building, RoB is certainly an important quality-assurance step to 
take. Our inter-rater agreement of QUIPS was initially weak and required a learning phase, but 
it improved somewhat after a learning phase was incorporated. Some domains and prompting 
items were more difficult to rate, and suggestions on how to improve RoB assessment in 
prognostic research in the field of chronic pain were provided.  
Primary data on prognosis showed that patients who were working, or who had had only a short 
period of time off work, had a better prognosis for both main outcomes, physical functioning 
and emotional functioning. In line with results from the evidence synthesis, positive beliefs in 
recovery and ‘good’ initial emotional health were important for physical functioning. In 
contrast, a poor initial physical functioning indicated a better prognosis. Likewise, poor initial 
emotional health indicated a better prognosis for emotional functioning, but a strong sense of 
life control (i.e. less life impact) was also of importance. Hence, some baseline factors go in a 
‘better in better out’ direction while others are ‘the worse the better’, presenting a complex 
prognostic picture for the complete understanding of good clinical follow-up on functioning 
and HRQoL. Regarding IMPR effectiveness, IMPR consistently proved to be clinically 
effective on our main outcomes as well as for our secondary outcomes. On the contrary, 
regarding the study hypothesis that a longer duration IMPR program would be superior to a 
shorter one, IMPR proved equally effective irrespective of program duration.  
 
6.2 PROGNOSTIC FACTORS FOR A POSITIVE OUTCOME AFTER IMPR 
The results from Studies I and III provide a basis for some important reflections. Study I 
investigated physical functioning based on PROMs only while Study III investigated both 
physical and emotional functioning, with the added value of incorporating socio-demographic 
factors in the prediction analyses as well. Common to both outcomes in the primary data was 
the importance of the employment variable, which showed that work was consistently a 
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protective factor for improvement. There seemed to be a linear trend, with a less positive effect 
as time off from work increased. Efforts to avoid delay therefore seem to be of importance for 
a better general prognosis. These results are further corroborated by other studies, also showing 
the importance of the work connection with HRQoL (109, 110). 
A recent study, based on registry data from SQRP and linked with the Swedish Social Insurance 
Agency, investigated patterns of sick leave one year prior to IMPR and found an increase in 
sick leave prior to participating in IMPR, consisting of a larger percentage of full-time and 
partial sick leave, which later decreased again in the two years after rehabilitation. Rivano 
Fischer et al. emphasized the importance of further research into sick leave patterns before and 
after IMPR, in conjunction with PROM (111). Their study also showed that a longer period of 
sick leave before IMPR was found to be associated with lower rates of return to work (RTW), 
while those not on sick leave prior to IMPR had higher RTW. Further research into the 
prognostic value of work (and the time-period of sick leave prior to rehabilitation) is required. 
This kind of research, however, is difficult to perform and very nation and time specific, since 
policy alterations on sick leave, for instance, can change the meaning of the prognostic factor 
without a person having changed in other ways. Our cohort was taken from a period after the 
major revision in social insurance regulations in 2009. Also, further research into what it 
actually is in the ‘Work-factor’ in this specific population that constitutes its protective part is 
needed. One must also take into consideration that long-term sick leave might be a result of 
unsuitable work due to a patient’s physical and mental condition that could prevent them from 
being able to return to working life in general. 
The results from both the systematic review and meta-analyses (Study I) and primary data 
(Study III) showed that physical functioning was important for prognosis. When it comes to the 
more performance-based or objective prognostic factors there seems to be a lack of studies 
available using other data collection methods than PROMs for physical functioning. In our 
systematic review (Study I), we could not pool the estimates due to limited data, but our 
narrative synthesis showed no association for performance-based physical function, which was 
in line with van der Hulst et al. As indicated, however, when comparing associations on self-
assessed physical function, we found, similar to van der Hulst et al., that these PROMs were of 
value in both our data from the systematic review/meta-analysis and primary data (59). 
Concerning the direction of this association, both in our narrative analyses and in van der Hulst 
et al., both high and low physical functioning could predict a positive outcome, leading to 
somewhat inconsistent results. Taken together, a similar discrepancy was found between 
Studies I and III, with the meta-analysis, in Study I indicating a positive association between 
high baseline functioning and improvement while the regression model in Study III showed a 
negative association. The reason for this is presently unclear. Except for initial physical 
functioning as a prognostic factor, however, the baseline prerequisites for an improved physical 
functioning seem to illustrate a good “better in better out” relationship, and indicate the 
importance of healthcare professionals working with behavior change in relation to exercise, 
activities, and increasing function. To improve, one needs to be in ‘pretty good shape’ mentally 
and have access to adaptive coping mechanisms. When it comes to the outcome mental 
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functioning, results from Study III indicated that people in worse shape are more likely to 
improve illustrating “the worse, the better”. This is in line with findings in other recent studies 
(112, 113). One possible explanation could be that here it is the perceived support from the 
team and the environment that is the strengthening component. Further research is necessary 
to understand more of this somewhat complex clinical presentation. 
For Pain, the prognostic value seems inconclusive as the results differ between Studies I and 
III. In the meta-analyses, the initial pain level and pain duration were not significantly 
associated with outcome, despite indicating the direction that low initial pain was better. In 
Study III, pain was somewhat associated with outcome, and a lower pain intensity was 
prognostic for improvement in physical functioning. Both studies indicated the same direction 
of the association, but this was not confirmed by the pooling of data. Perhaps this was due to a 
power problem as in previous reviews (58, 59). Study III, based on primary data, is uniquely 
large-scale and well powered, and if these new data were to be aggregated with previous forest 
plots in Study I, the effect size and confidence intervals would probably change.  
The results from the systematic review and meta-analysis (Study I) showed that psychological 
factors were of importance. Results showed that low levels of emotional distress predicted a 
better physical functioning in long-term follow-up. This was partly supported by our primary 
data study, where high SF-36 MCS was significantly associated. Although the effect size for 
SF-36 MCS in Study III was small, one must remember that the presented odds ratio represents 
its continuous scale from 0-100. Parallel to this finding, another factor, HADS-A, emerged as 
significant, however, indicating the opposite: high anxiety was associated with improvement 
in physical functioning. It is difficult to explain why this result emerged, but it is believed that 
it could be related to IMPR effectively targeting aspects of anxiety, however this needs further 
study. 
Cognitive and behavioral ‘coping’ factors presented a joint picture; low levels of cognitive and 
behavioral risk factors, such as fear avoidance and pain catastrophizing, predicted a better 
physical functioning at long-term follow-up. These results seem reasonable, as these factors 
are known to hinder functioning, which is why modern IMPR targets this domain in many 
ways, from pain school, to graded activity, exposure etc. Parallel to this, high levels of cognitive 
behavioral protective aspects, such as optimism, self-efficacy, and sense of control, were 
associated with high physical functioning. In this respect, positive affect, resilience, and 
sustainability are concepts that have received increased attention where chronic pain research 
is concerned. It is believed that an increased focus on positive, psychological, protective, and 
resilience factors may provide an opening to re-instituting best available physical function. 
Sustainability can be defined as the “ability of a person to move towards long-term positive 
outcomes in life in the presence of adversity”. An increased focus on targeting not only 
recovery from disability but also the promotion of an upward spiral of sustainability, providing 
a buffer for the downward spiral seen in Figure 9, has been advocated (114).  
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Figure 9. Recovery and sustainability in the field of chronic pain.  
With permission from the publisher. Eur J Pain. 2017;21(8):1301-15. (114). 
 
6.3 INTER-RATER AGREEMENT RELIABILITY OF QUIPS 
The quality of the studies upon which evidence will be built is indeed of great importance (115) 
and, therefore, reliable instruments are necessary. Many other instruments use sum scores as 
an indication of total RoB, but in QUIPS the use of a sum score is not recommended as 
emphasis is put on scientific judgment and a sum score could give the appearance of false 
objectivity. It is important to understand that the instrument warrants a judgment to be made, 
and the final judgment is based on an informed discussion. Hence the assessment is not 
intended to be deterministic, and it also allows for some degree of subjectivity.  
It was evident that it was not so easy to agree during the independent assessment, which was 
illustrated by the low kappa. On the other hand, the agreement increased over time in the second 
round. This highlights the presence of a learning phase. Also, it was evident that studies with 
good methodological quality were easier to agree upon. Sometimes judgment was also 
hindered by poorly reported data in studies, and here more variance in the interpretation was 
present. However, as the independent rating is just the first step of a scientific judgment, any 
discrepancies in judgment were revealed and dealt with. A poor inter-rater agreement in this 
stage is therefore not problematic for the final decision with regard to RoB and GRADE 
assessment – instead it is the prerequisite of a scientific discussion. We believe, however, that 
it is helpful to have knowledge on the inter-rater agreement analyses early on in the process to 
identify problematic areas as these may need more detailing, for which suggestions to 
clarification were given in Study II. Early inter-rater agreement analyses can also help reveal 
issues within (e.g. how many “nos” are required before downgrading a level on the RoB scale) 
or between particular domains, for instance we discovered that one methodological flaw in a 
study could be judged within two different domains, which resulted in low agreement until 
discovered.  
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It is difficult to compare Study II with previous studies on the inter-rater reliability of QUIPS 
due to a different context of prognostic research. Our study in the area of chronic pain was 
challenging due to the large variety of symptoms present, and the fact that we evaluate 
prognostic factors across multiple outcomes and other methodological difficulties such as low 
attrition in observational rehabilitation research.  
 
6.4 EFFECTIVENESS OF IMPR 
Following an IMPR program, patients improved significantly post intervention and the effects 
were sustained at the 12-month follow-up. Our findings are mostly consistent with several 
systematic reviews, which have concluded that IMPR generally is effective, but with small to 
moderate effects (21, 47, 50, 61, 63), and also in line with previous primary studies reporting 
long term improvements on pain, and quality of life (116, 117). Contrary to our findings and 
the general notion, a recent umbrella review assessed the strength of the evidence for 
effectiveness of IMPR and concluded that there is currently no robust evidence for the 
effectiveness of IMPR in any outcome, with the possible exception of decreased pain short 
term (118). One major contribution to this conclusion was the small number of studies included 
in the synthesis and the fact that many studies were susceptible to small sample sizes. Our 
results are based on large, real life empirical data, with wide national representativeness.  
Importantly, although our results showed positive effects at a group level, data on our MCID 
indicated that around 20% of the patients deteriorated at least one MCID on the primary and 
secondary outcomes, and that is despite receiving IMPR. This is in line with recent findings 
from Vartiainen et al. (110), who also showed that while QoL was improved in nearly half of 
the patients, there were also approximately 30% who reported a clinically important 
deterioration at 12-month follow-up after rehabilitation. Until now, research results that show 
good (or no) overall group effects have rarely shown subgroups which, paradoxically, may tend 
to deteriorate, possibly because they often lack power to motivate such grouping. It is believed 
that the identification of subgroups has the potential to give important indications on how IMPR 
may be better tailored to each patient, and possibly also show which patient groups are in need 
of another type of rehabilitation. Further research presenting and further analyzing such 
bidirectional data is thus warranted to increase knowledge of possible explanatory 
characteristics. 
 
6.5 EFFECT OF TREATMENT DURATION ON HRQOL 
The motivation for emphasizing treatment duration as a between-group factor was that we 
hypothesized that it takes time for behavior change to be learned and absorbed into individuals’ 
day-to-day routines (65). Contrary to our hypothesis, IMPR proved equally effective 
irrespective of program duration. Longer IMPR programs were not superior to shorter 
programs and although there was indeed a statistically significant between-group effect 
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favouring moderate vs. short programs, the difference was negligible and not detectable on 
MCID. Our findings are, however, in agreement with findings from systematic reviews that 
have examined the influence of treatment duration in the context of dosage (50, 118). 
Waterschoot et al. concluded that “on the basis of current literature it is unknown how many 
hours, months, or weeks are needed to achieve the best effects” (50). Using a meta-
epidemiological approach, the meta-analysis by Dragioti et al. (118) examined the influence of 
treatment duration in the context of dosage, in patients with non-specific chronic low back pain, 
and they concluded likewise that treatment duration had no overall influence on the reported 
effects. However, in subgroup analyses, larger effect sizes for pain and disability emerged in 
favour of a long program with non-daily contact, while for quality of life, a shorter duration 
was favourable. In our study, however, the results were consistent across outcomes, with no 
between-group effects, or for SF-36 physical health, a statistical significant but clinically 
negligible effect favouring the moderate program. Both the above-mentioned systematic 
reviews based their evidence synthesis on available literature. Our results may add to theirs, by 
using large sample, pragmatic register-based primary data. We believe our study design and 
our results hold for what can be expected of a well-designed controlled study, by emulating, as 
far as possible, a register-based RCT.  
 
6.6 METHODOLOGICAL CONSIDERATIONS 
6.6.1 External validity Study I-IV 
Regarding the generalization within the context of the intervention and the study population of 
interest, Table II shows that the patients included in the systematic review and meta-analysis 
(Study I) are corresponding well to the patients included in the national registries (Studies III 
and IV), in respect to gender, age, and pain duration. In Studies I, III, and IV, evidence was 
derived from longitudinal and/or pragmatic cohort studies, which commonly have higher 
external validity compared to experimental randomized controlled trial studies (119). IMPR, 
however, could differ between different countries and continents, since rehabilitation centers 
around the globe work differently. Most of the scientific literature used in Study I, was based 
on data from rehabilitation centers from Western countries, such as USA, a number of 
European countries, Australia, and New Zealand, and the results of the systematic review/meta-
analysis should therefore be extended to these countries, or to countries with similar conditions. 
As relevant for Study II – results on inter-rater agreement – the raters were experienced and 
senior researchers in the field of pain rehabilitation, and the results should therefore be 
generalizable to raters with a similar specialist level. In addition, the results extend to QUIPS 
when judging the quality of the literature on prognostic factors, and with prompting items 
within the research field of pain rehabilitation. Our recommendations, however, could inspire 
researchers from other fields to work in a more structured manner, since much of the problems 
that were identified were rather generic and related to methodological issues such as poor 
reporting, multiple outcomes, and statistics. Moreover, since QUIPS is the recommended tool 
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to be used by the systematic reviews and meta-analyses in the Cochrane group, this study is of 
importance for evidence-based medicine, which is the base for general future rehabilitation 
recommendations for individual patient treatment.  
 
6.6.2 Internal validity studies I-IV 
 Study I 
The strength of this systematic review/meta-analysis is the broad approach that was used in 
order to synthesize the factors of importance for physical functioning, rather than exploring a 
single prognostic factor impact or a selected diagnosis within the chronic pain-population. The 
methodology used in this systematic review/meta-analysis follows strictly the standard 
recommendations and by the well-established Cochrane Prognosis Methods Group, and 
GRADE groups and the methodology used in the study has been pre-reviewed in a study 
protocol which was published before starting the analyses (79). Although the initial selection 
of papers based on title and abstract was mainly performed by only one reviewer, the screening 
process had a robust arrangement with randomization of studies and independent teams 
constituted by a senior and junior researcher (Figure 5). The broad selection of studies resulted 
in high heterogeneity, measured by I2, for almost all comparisons (range: 48% to 94%), but 
there were no systematic reasons for this variance. Sensitivity analyses showed that the results 
were robust when controlling for different factors such as follow-up time, study quality, and 
statistical analyses. Although there was an unacceptably low inter-rater agreement for some 
RoB domains, it was not difficult to obtain consensus on the overall RoB scores. 
One of the limitations of the systematic review/meta-analysis that could have occurred is the 
presence of information bias, since “gray” and non-English literature was omitted. In addition, 
the grouping of factors and outcomes, which were measured with various instruments could 
have increased heterogeneity and for that reason, incompatible and vague measures were 
excluded from the analyses. Another source for limitation of the study could be the low study 
quality of the included studies. However, it is not clear if the studies with low quality were 
actually biased, since in many of the studies there was a lack of relevant reporting on for 
example, study participation and attrition. A final point of limitation could be the occurrence 
of publication bias. The relatively small number of studies reporting on each comparison 
hampered the possibility for making detailed and meaningful analysis of funnel plots.  
 Study II 
The use of systematic review and meta-analysis has increased over the years, since they are of 
the highest importance for evidence-based medicine, and issues of quality assessment have 
currently been structured in order to reach transparency in the process. One strength of this 
study is that not many previous studies have been published in the field of rehabilitation of 
chronic pain on experiences and learning processes of using methodological tools, and tried to 
improve such instruments, which is what this study has attempted to do. 
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The number of raters (and papers) included in our analyses was relatively small and this could 
be an important limitation of this study. This resulted in low prevalence in some of the cells, 
especially when performing sub-group analyses. Perhaps the inclusion of the third (junior) 
reviewer could have increased the inter-rater reliability to some extent. The lack of a “true 
RoB” for each paper could have led to an overestimation of the Kappa agreement if both raters 
made the same error. 
 Study III 
A strength of this study was the large sample size that had national coverage. A relatively high 
proportion (47%) of patients were lost to follow-up, which is similar to earlier studies with 
long-term follow-up (84). A crude missingness analysis showed, however, that the non-
responders were similar to the responders on all pain characteristic variables and self-rated 
health measures, but a larger proportion of the non-responders was born outside Europe and 
had a somewhat lower degree of vocational connection. This may indicate that information on 
study participation and questionnaires was not successfully adapted for foreign participants. 
Despite the width of tested potential prognostic factors, the degree of explained variance in 
final regression models did not exceed 21%, indicating that for the complete prediction of 
outcome, much still remains unrevealed.  
 Study IV  
The independent variable Duration: Some programs at certain clinics are relatively stipulated, 
others permit more variability in the treatment according to the patient clinical status. Better 
‘recording’, or register-documenting, of actual treatment is, however, needed, particularly since 
no standardized programs exist (45) with regard to content, duration, intensity, and adherence.  
Since the independent variable on IMPR duration is an instrumental variable, theoretically the 
association between the dependent and independent variables cannot be influenced by 
confounders. Still, we tested if all pre-intervention data and the variable “treatment days per 
week” were related to the independent variable (treatment duration) and could have a potential 
to confound any associations between dependent and independent variables in the between-
group analyses. Regression analyses showed though that a longer duration was somewhat 
related to “treatment days/week” (r = -0.25), indicating that the longer duration groups have 
less treatment days/week. This variable was therefore adjusted for in all our between-group 
GEE-analyses, as was all baseline data.  
Our comparison groups were not randomized, and although our analysis allowed controlling 
for between-group differences, unknown potential confounding has not been controlled for. 
 
6.7 STATISTICAL CONSIDERATIONS 
Study I: Using the inverse variance method in the meta-analysis, the weight given to each study 
is the inverse of the variance of the effect estimate (i.e. one over the square of its standard 
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error). In this way larger studies are given more weight than smaller studies, which have larger 
standard errors. This choice of weight minimizes the uncertainty/ imprecision of the pooled 
effect estimate.  
Studies III and IV: Discussion on using the Minimal clinically important difference as cut-off 
for improvement (Study III) and for improvement and deterioration (Study IV). Logistic 
regression models require cut-offs, for which a clear rationale is not always present. For the 
dichotomization of outcomes and the definitions used for improvement we used previously 
reported MCID definitions, however, to our knowledge these are not yet comprehensively 
validated in patients with chronic pain, which suggests some attention is required to what a 
good outcome represents using MCID (91). Also, in Study IV, we based the analyses on 
proportion of MCID improvement and deterioration on the assumption that MCID scores 
would not differ bidirectionally, which of course could be argued upon.  
 
6.8 GENERAL DISCUSSION 
In this thesis, three studies concerned various aspects of prognosis. In this respect, it is 
important to remember the distinction in interpretation between prognostic and predictive (120, 
121), although a factor may be a little of both, the prognostic factor indicates the likely outcome 
(for instance disease recurrence) irrespective of treatment, whereas predictive refers to the 
likely benefit after treatment, compared to the patient’s condition at baseline. Our bivariate 
outcome was created to reflect an improvement – and therefore also give some indication of 
the likely benefit interpreted as a result of the treatment. However, and here an important 
distinction is necessary, prognostic factors are not intended for treatment selection, and not 
suitable for interpretation as if those lacking the prognostic factor would benefit less from the 
treatment.  
Taken together the prognostic factors revealed from Studies I and III, these studies point to a 
clinical picture, where the baseline prerequisites for an improved physical functioning – ‘a 
better in better out’ – here can be interpreted as to be able to work with behavior change in 
relation to exercise, activities, increasing function. One needs to be in ‘pretty good shape’ both 
physically and mentally as well as have access to adaptive coping-mechanisms. When it comes 
to mental functioning, results are based on Study III and show another clinical picture, 
indicating here that the person in worse shape is more likely to improve. 
The outcome measures used in this thesis relate mostly to general measures of functioning, and 
to general life impact concepts such as HRQoL. This seems of relevance as this is an overall 
target of rehabilitation in general, and specifically in the particular case of chronic pain 
considering the low levels of quality of life reported for this population. Even though marginal 
effects were modest, hopefully they represent a perceived change of life impact of their pain 
condition. Considering the focus on physical and mental core domains in this thesis, it may be 
that the equally important third, social dimension, in this concept is not as well reflected in the 
way we assessed HRQoL.  
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Physical exercise and conditioning is definitely one of the cornerstones of IMPR practice. 
During this project we have come across empirical data that suggest there may be an imbalance 
in measures relating to physical functioning compared to emotional and psychosocial 
measures, for instance those reported in the SQRP. Psychosocial measures are evidently of 
greatest relevance, but where does all the information on physical fitness and strength training, 
i.e. the more proximal dimensions of physical functioning, end up? Is it possible that there is 
an unfortunate loss of information that is potentially relevant for our understanding of IMPR 
effectiveness? 
With our chosen MCID-levels, at the least quite a large proportion improved over time. As 
indicated, however, some also experienced decreased ratings, equivalent to MCID levels, and 
some remained unchanged. Of course, one wants to go deeper into those who did not improve 
or who deteriorated. And also, we need to validate further whether these MCID levels were 
appropriate. Another issue that could be discussed is whether the reverted MCID were an 
appropriate measure? 
All in all, the studies included in this thesis could be of importance to the existing evidence 
base, and in the long term they could provide guidance to all healthcare personnel working to 
make a difference to sufferers of chronic pain conditions. 
 
6.8.1 Clinical implications 
From the systematic review and from the large quality register, it was evident that measures of 
physical functioning were not as rich in detail as those of emotional functioning. Considering 
the comprehensive approach taken to physical conditioning and less interference with activities 
in IMPR, these domains seem under-evaluated, but could easily be implemented with the many 
new performance based ways to measure physical activity. 
Modifiable factors, positive affect, treatment expectancy, hope, control, active coping 
mechanisms? All of these are surely already addressed – but perhaps with more focus on 
decreasing negative cognitive behavioral coping such as fear avoidance, in order to restore 
health. An interesting, complementary way, would be to increase sustainability by targeting 
protective cognitive behavioral factors, such as Acceptance and Commitment Therapy, which 
is gaining increasing ground. This might be an area where further gains can be achieved.  
More data is needed on received actual intervention. A minimum level of information needs to 
be transformed to the SQRP, to enable analysis of progress in more detail. 
For researchers using QUIPS, the following tips are highlighted. First, the importance of 
agreeing on the judgment of the prompting items in advance, an initial pilot on 2-3 articles can 
help identify areas in need of clarification. Secondly, plan for an early tuning-discussion with 
the team (after 5-10 articles) to help resolve dilemmas and disagreements that have arisen in 
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praxis. Finally, calculate Kappa early, as a way of identifying domains that may be in need of 
harmonization. 
 
6.8.2 Future research 
 Future prognostic research needs to investigate how personal and treatment factors in 
combination may explain more of the ‘unexplained variance’,  
 Since some of the present baseline factors go in a ‘better in better out’ direction while 
others are ‘the worse the better’, presenting a complex prognostic picture, there is a need 
for further studies on what is behind such result for the complete understanding of good 
clinical follow-up, 
 In addition to how prognostic variables coincide with the clinical landscape, with the help 
of the present results, prognostic models and clinical tools are now needed for how these 
variables can be used for adaptation to the individual patient. In connection with this, 
research is also needed on how such models can be implemented in the IMPR team work, 
 There is a need for accessibility and knowledge to generate register-based randomized 
controlled trials that can be linked to SQRP. In this way, questions on different treatment 
approaches (e.g. IMPR intensity) can – I believe – be answered with clearer causality, and 
at relatively low costs,  
 There is also a need for research collaborations that provide broad access to linked 
registry databases, that SQRP is linked to the social insurance database as well as to drug 
registers and e.g. registers that handle socio-demographic data. In this way, unanswered 
questions can be approached that relate more strongly to the patients' social situation and 
societal participation.   
 The psychometrical properties of the outcome instrument used in SQRP needs more 
research,  
 There is – I believe – a need to recognize physical activity patterns by using modern 
machine learning algorithms on activity tracker data, and by adding such objective data 
investigate what patterns predict clinical relevant improvements on clinical outcomes. 
That is since the research in the field of physical activity has been shown promising in 
various patient group suffering from musculoskeletal disorders.  
 Finally, there is a great need to link the knowledge gained from PROMS with what can be 
measured at biomechanical laboratories on human movements in this major group. Such 
research is fundamental for how rehab exercises and physical activity should be adapted 
and balanced, and research related to these issues has begun as a result of this thesis work. 
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7 CONCLUSIONS 
 
 Evidence for prognostic factors that precede IMPR was identified, providing suggestions 
for the targeting of modifiable factors in clinics and in future clinical trials. Specifically, 
there was a moderate to low level of evidence that better physical functioning after IMPR 
in patients with chronic pain is predicted by high levels of initial self-assessed physical 
functioning, low levels of emotional distress, low levels of cognitive and behavioral risk 
factors, and high levels of protective cognitive and behavioral factors, but not by initial 
pain level or pain duration (chronicity). 
 
 Inter-rater agreement using the Quality in Prognosis Studies-tool improved over time and 
despite relatively weak inter-rater agreement, this proved to be a useful tool for assessing 
the risk of bias when performing a meta-analysis of prognostic studies in pain 
rehabilitation. The main strength of this tool is that it requires raters to discuss and 
investigate important aspects of study quality. Hence, the quality assessment of published 
results needs systematic consensus work between assessors. 
 
 Employment status, younger age, high beliefs of restored health, high emotional health, 
low levels of pain, and pain interference, but high levels of anxiety and worse initial 
physical health all predicted Physical functioning. Emotional functioning, on the other 
hand, was predicted by employment status, high general activity, high sense of life 
control, and of European origin, but worse initial emotional health, indicating a complex 
prognostic picture for the complete understanding of good clinical follow-up. 
 
 The effectiveness of IMPR programs for patients with chronic pain was supported across 
all outcomes in the biopsychosocial spectrum in the short term (post-intervention) and 
long term. Still, there was a noticeable proportion of patients who deteriorated during the 
follow-up period.  
 
 Despite some statistical differences favoring moderate-duration IMPR, no clinically 
meaningful differences emerged for comparative effectiveness across all outcomes, which 
suggests that the IMPR content and team collaborative aspects can be highlighted in 
future rehabilitation developments. 
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